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Abstract 
The immune system must be controlled to prevent damage caused by inappropriate 
responses and extended inflammation. Regulatory T cells (Tregs), known to be 
generated by the thymus, must be maintained in the face of an ever-increasing human 
lifespan and associated thymic atrophy in order to protect the host, but whether they 
are maintained by expansion of pre-existing Tregs or conversion of conventional T cells 
is not yet known. 
 
There are known to be two subsets of FOXP3+ regulatory T cells: naive and memory 
cells, expressing CD45RA and CD45RO respectively. In this work the characteristics of 
CD45RA+ and CD45RO+ regulatory T cells were investigated in healthy adults. We 
found proliferative and phenotypic differences between the two subsets, and evidence 
that CD45RA+ Tregs can replenish the memory Treg pool on activation. It is, however, 
becoming more accepted that CD45RO+ Tregs are also likely to be composed of many 
cells that were converted externally to the thymus from conventional T cells, and our 
work suggests a mechanism for this conversion: anergy induction. We also found that 
the two Treg subsets are able to migrate to disparate tissues. Investigation of 
cutaneous immune responses in vivo revealed the presence of a significant proportion 
of Tregs, their numbers rising and falling in concordance with the number of 
conventional T cells. 
 
Finally, these investigations of Treg subsets were extended to investigate atopic 
dermatitis (AD), a hypersensitivity condition in which Tregs are implicated. We found 
significantly fewer CD45RA+ Tregs among AD patients, with unexpectedly low rates of 
turnover of these cells in AD skin, despite the presence of high proportions of 
CD4+FOXP3+ cells. 
 
Overall, the findings from this study imply disparate roles for CD45RA+ and CD45RO+ 
Tregs, and provide further evidence supporting a role for dysregulated regulatory T cell 
function in the pathogenesis of atopic dermatitis. Abbreviations 
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syndrome Abbreviations 
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Chapter 1. Introduction 
 
1.1 The immune system 
The immune system relies on a complex interplay of cells and molecules in order to 
protect the host from infection by pathogens. Although barriers, such as skin and 
lysozyme-containing saliva, do exist, they are occasionally breached by infectious 
organisms such as viruses and bacteria. There are many different types of pathogen, 
all with different strategies for persisting within the host; as a result, the immune system 
employs a number of different cell types with different specialised functions. 
 
All immune cells, or leukocytes [1], are ultimately generated in the bone marrow from 
haematopoietic stem cells [2]. However, they subsequently develop via differing routes 
of maturation and play discrete roles within the immune system. Innate immune cells, 
such as neutrophils, macrophages, eosinophils and NK cells, are unable to recognise a 
specific antigen from a particular pathogen, but are able to recognise that an organism 
is likely to be dangerous. They respond quickly to infection: neutrophils arrive at the 
site of pathogen invasion within the first few hours [3]. T cells and B cells form part of 
the adaptive arm of the immune system: they are highly varied and each individual B or 
T cell is specific for a slightly different antigen [4, 5]. They are initially slow to respond 
to primary infection, as the rare cells specific for the required antigens must proliferate 
before they can reach sufficient numbers to be effective. However, if the pathogen 
invades the host a second time, a much faster secondary immune response is 
generated by the adaptive immune system because of the memory cells generated 
during prior exposure [6]. 
 
Neutrophils and macrophages are phagocytic cells: they engulf, and subsequently 
digest, pathogens [7] which they, like many innate cells, recognise by the presence of 
pathogen-associated molecular patterns (PAMPS). These include bacterial products 
such as lipopolysaccharide (LPS) from the microbe cell wall, viral products such as 
double-stranded RNA and fungus-specific molecules, like zymosan [8]. PAMPs are 
detected by pattern-recognition receptors (PRRs) of which the most numerous are toll-
like receptors (TLRs) [8, 9]. Macrophages are also able to control the conduct of the 
subsequent immune response, by releasing the appropriate cytokines to favour either a 
cell-mediated or an antibody-mediated response. Other innate immune cells include 
eosinophils, which are, like neutrophils, phagocytic [10] but also contain granules which Chapter 1. Introduction
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The gap between the innate and adaptive immune systems is bridged by dendritic cells 
(DCs) [21, 22]: although not capable of forming memory cells, they are able to signal to 
T and B cells to alert them to infection. These cells are found in their immature state in 
the tissues [23] and possess long cell extensions [22] with which they sweep the 
environment; if they detect a pathogen or foreign cell, they become activated, migrating 
to the lymph nodes and presenting antigens from the pathogens to T or B cells [24, 25]; 
hence, they are termed antigen-presenting cells (APCs) [25]. Although activated DCs 
are able to initiate an immune response, immature DCs have more recently been found 
to exert tolerogenic effects on the immune system, inducing IL-10 production and 
regulatory (suppressive) function in T cells they interact with [26, 27]. 
 
B cells and T cells are lymphocytes, like natural killer cells, and circulate in the 
bloodstream and the lymphoid system to access lymph nodes. These are 
compartments allowing the interaction of (normally tissue-resident) antigen presenting 
cells and lymphocytes, which enter the lymph node from the bloodstream via high 
endothelial venules [28]. Once the lymphocytes are activated, they migrate to the 
original source of the antigen (the site of infection) and destroy the pathogen. 
 
B cells develop in the bone marrow and are able to produce antibody, or 
immunoglobulin (Ig): the B cell receptor (BCR) is surface-bound immunoglobulin [29]. 
There is an extraordinarily large variety of potential BCRs, all with slightly different 
specificities [30], resulting from the capacity of B cells to rearrange the DNA encoding 
their surface antigen receptors; T cells also have this ability, resulting in a broad 
spectrum of T cell receptor (TCR) specificities as well [31, 32]. BCRs recognise a 
protein in its natural conformation. Once activated, by recognising its specific (cognate) 
antigen, the B cell is stimulated to divide many times and undergoes a process termed 
somatic hypermutation, whereby the BCR is mutated slightly each time: those cells 
possessing new BCRs with the highest specificity for the antigen divide again and so 
on, until the affinity of the receptor for the antigen is much stronger [29]. The B cells 
generated by this process are conventionally accepted to continue down one of two 
different routes: they can generate plasma cells, which generate and secrete large 
quantities of antibody, or memory B cells, which can participate in future reactions [33]. 
Secreted antibody has the same specificity as the plasma cell’s BCR and binds to its 
cognate antigen at its variable (Fab) region [34]. The other end of the antibody is termed 
the constant (Fc) region [34, 35] and can bind to receptors on other immune cells such 
as macrophages and neutrophils; when many antibodies are bound to one antigen, 
their Fc regions stimulate engulfment and destruction of the pathogen [36]. Chapter 1. Introduction 
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T cells exist in two major subgroups: CD4-expressing (CD4+) ‘helper’ T cells and CD8+ 
‘killer’ (cytotoxic) T cells, which recognise antigenic peptides bound to different MHC 
[37]. CD8+ T cells recognise peptides in the context of MHC class I (HLA-A, B or C). 
They secrete IFN-γ, express perforin and granzyme and act to destroy infected or 
cancerous cells. CD4+ T cells are MHC class II-restricted, recognising peptides bound 
to HLA-DR, DP or DQ. They are not usually thought to kill directly but instead play a 
more controlling role in the immune response, providing help to activate both B cells 
and CD8+ T cells to perform their roles. They can also produce a range of cytokines, 
influencing the course of the subsequent immune response [38, 39]. 
 
Activated T cells, like B cells, can become long-lived memory cells or more short-lived 
effector cells [40]. The ability of lymphocytes to generate long-lived cells with a highly-
specific receptor forms the basis of the phenomenon known as immunological memory. 
As noted above, naïve cells are difficult to activate initially; there are also very few 
naïve T cells able to recognise antigens from the same pathogen, and the same is true 
of B cells. This means that the (primary) adaptive immune response to a pathogen on 
initial encounter is relatively slow. However, circulating memory cells of a particular 
specificity are both higher in number and easier to activate than naïve cells, and also 
patrol the peripheral lymph nodes and tissues [40], enabling a secondary immune 
response to be much more rapid, often preventing the infection from taking hold 
altogether. The individual is hence said to be immune. 
 
Immunological memory is exploited in the field of medicine via vaccination, whereby 
attenuated or killed pathogens, or pathogen components, are injected into the 
individual, enabling the immune system to recognise and eradicate the pathogen if it 
should be encountered again [41]. 
 
1.1.1 CD4+ T cells 
Whereas CD8+ T cells release perforin and granzyme to destroy the infected cell, the 
primary function of CD4+ T cells is not killing (although they have been shown to be 
capable of this [42-44]). They specialise in the provision of ’help’ to both B cells and 
cytotoxic T cells, to enable these cell types to function more efficiently and generate 
memory populations [44-46]. CD4+ T cells are also able to skew the immune response 
depending on the combination of cytokines they release on activation: for example, Th1 
(T-helper 1) cells favour a cell-mediated, cytotoxic T-cell response and Th2 cells favour Chapter 1. Introduction 
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the activation of eosinophils and a humoral response [38, 39]. CD4+ T cells are the 
main focus of work contributing to this thesis. 
 
Generation and activation 
T cell generation is initiated in the bone marrow, but the developing cells migrate to the 
thymus to complete their maturation; while still in the thymus, they are termed 
thymocytes. As is the case with B cells, thymocytes somatically rearrange the DNA 
encoding their TCR in order to generate a large range of potential TCR specificities 
[32]. This rearrangement generates small circles of excised DNA, called T cell receptor 
excision circles (TRECs). These are not replicated as the cell divides, so cell 
populations with a higher TREC content can be assumed to have divided fewer times 
since their generation [47]. High TREC content therefore suggests a naïve T cell 
population. 
 
Once the novel TCR has been generated on each cell, its specificity is tested. T cell 
receptors recognise short stretches of peptide from the antigen only in the context of 
the MHC (major histocompatibility complex) [48, 49]. MHC class I presents peptides to 
CD8+ T cells, whereas CD4+ T cells are generally MHC class II-restricted, although 
exceptions to this have been reported [50].In the thymus, maturing thymocytes 
encounter MHC presenting self-antigen on thymic epithelial cells [51]. If the thymocyte 
does not recognise the MHC+peptide complex at all, it will die from neglect, whereas 
those thymocytes which respond to the presence of MHC receive survival signals; this 
is called positive selection. If it recognises it too strongly (and hence has the potential 
to be autoreactive), it is generally deleted: this process is termed negative selection 
[52-54]. Cells which react with low affinity for self peptide and MHC continue to mature 
and are released from the thymus as naïve T cells [55]. There are thought to be 
exceptions to this: sometimes, it is thought that strongly-reacting thymocytes may 
become anergic (unresponsive) or undergo receptor editing, or possibly become 
suppressive regulatory T cells (Tregs) [55, 56]. 
 
MHC molecules present peptides from processed proteins: MHC class I peptides are 
normally from proteins synthesised within the cell, whereas MHC class II peptides are 
generated via degradation of proteins within endosomal compartments [57]. Under 
normal conditions these are self-peptides, eliciting no immune response from the 
previously-tolerised circulating T cells. However, virally-infected cells display viral 
peptides on MHC class I. A very small number of mature CD8+ T cells will be able to 
recognise the combination of peptide and MHC molecule and will hence become Chapter 1. Introduction 
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activated and proliferate. Likewise, external antigens can be ingested and processed 
by professional antigen-presenting cells, and their peptides presented on MHC class II. 
This will activate the small proportion of CD4+ T cells whose TCRs recognise that 
particular peptide-MHC combination. 
 
TCR stimulation alone is not sufficient to completely activate mature T cells [58]. They 
require additional costimulatory signals, for example from CD28, which binds the 
dendritic cell-expressed molecules B7-1 (CD80) and B7-2 (CD86) [59]. These 
costimulatory molecules, along with signalling molecules and the CD4 or CD8 
coreceptor, cluster around the TCR as the T cell and APC form a stable interaction 
called the immunological synapse (IS) [60, 61]. 
 
CTLA-4 is also present in the IS structure. This is an inhibitory molecule, which also 
binds B7-1 and -2 but with a much higher affinity than CD28 [59]. Expression of CTLA-
4 is tightly regulated: it is not present on resting CD4+ conventional T cells and must be 
synthesised de novo after activation [59]. Once it has been upregulated at the surface, 
it is rapidly endocytosed again: this tightly-regulated cycling provides a check on CTLA-
4 surface expression levels [62]. Although CTLA-4 is known to inhibit T cell activation, 
a supposition supported by the fatal lymphoproliferative syndrome seen in CTLA-4 
knockout mice [63], the precise mechanism by which it inhibits activation is still a 
matter of debate [59]. 
 
Naïve T cells require extremely strong costimulatory signals in order to be activated for 
the first time, which can only be provided by a professional antigen-presenting cell 
(APC) – conventional DCs are the only cells so far discovered to have this ability [21]. 
These controls help to further reduce the possibility that self-reactive cells could 
become activated and attack the host. 
 
Differentiation 
T cells leaving the thymus directly after maturation are referred to as ‘naïve’ and 
express the long splice variant of CD45, CD45RA [64-67]. They also express high 
levels of the costimulatory receptors CD27 and CD28 [64-66, 68] as well as homing 
markers that direct them to the lymph nodes: CD62L and CCR7 [64]. It has been 
proposed that naïve cells can divide around two to three times before losing expression 
of CD45RA [69, 70]. ‘Truly naïve’ recent thymic emigrants (RTEs) have been 
suggested to be identifiable by their coexpression of CD45RA and CD31, an adhesion 
molecule also known as platelet endothelial cell adhesion molecule-1 (PECAM-1) [69, Chapter 1. Introduction 
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71]. CD45RA+CD31+ T cells have been shown to have longer telomeres and higher 
quantities of TRECs (T cell receptor excision circles, formed when the maturing 
thymocyte rearranges its T cell receptor (TCR) and diluted with proliferation of the pool) 
than the CD45RA+CD31- pool [69], suggesting that these cells have divided fewer 
times. 
 
After encountering cognate antigen, these cells begin to proliferate and undergo a 
process of differentiation, where these surface proteins are gradually replaced with 
others. As they differentiate they become known as central memory and then effector 
memory cells (see Table 1) [40]. CD45RA is downregulated and the shortest splice 
variant of CD45, CD45RO, begins to be expressed instead [64, 65, 67], and CD27 and 
CD28 are sequentially lost as the cell becomes more differentiated (CD8+ T cells, 
however, lose CD28 first) [64, 66-68]. 
 
As their surface phenotype alters, so does their function. Naïve CD4+ T cells produce 
large amounts of interleukin 2 (IL-2), a cytokine that encourages T cell survival and 
growth [72]. However, on stimulation they are thought to follow distinct pathways of 
differentiation to become one of four helper T cell subsets, producing different 
cytokines, depending on cues they receive from the stimulating antigen presenting cell 
[73]. Th1 cells produce large quantities of the pro-inflammatory cytokine interferon-
gamma (IFN-γ), useful in viral infections and for clearing intracellular bacterial 
infections [38]. Th2 cells, in contrast, produce IL-4 and IL-13, which favour an antibody-
mediated response [38, 39]. CD4+ T cells can also differentiate into Th17 cells, which 
produce the pro-inflammatory cytokine IL-17, thought to be beneficial in combating viral 
and fungal infections but also implicated in many autoimmune conditions [74-76]. 
Finally, CD4+ T cells have also been suggested to differentiate into suppressive 
regulatory T cells under certain conditions [77, 78]. CD8+ T cells also change function 
as they differentiate: they lose their capacity to generate IL-2 [79] and have been found 
to become increasingly cytotoxic as they become more differentiated [68, 80] as well as 
releasing larger quantities of IFN-γ [68]. 
 
One other gradual change taking place as T cells differentiate and divide is their loss of 
telomeric repeats at the end of chromosomes. Telomeres are long sections of DNA at 
each end of the chromosome containing only hexameric (GGGTTA) repeats and are 
gradually eroded with repeated divisions of the cell; they exist to prevent the loss of 
coding genetic material from the DNA strand, as well as to maintain stability of the 
chromosome [81]. The loss of genetic material from chromosomes on their replication Chapter 1. Introduction 
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results from the linear nature of eukaryotic DNA: DNA polymerase, the enzyme that 
builds the new strands of DNA using the existing strands as a template, cannot quite 
replicate the nucleic acid to the end of the strand [82]. It can only copy DNA in a 5’ to 3’ 
direction (see Figure 1.2); paired DNA strands run in opposite directions, so one must 
be replicated in short sections, called Okazaki fragments, as the DNA opens [83]. DNA 
polymerase uses an RNA primer to initiate each new DNA strand or fragment, which is 
then removed from the template strand, leaving a gap. This gap can be filled by an 
exonuclease and DNA ligase, but the gap at the very end of the strand cannot be filled, 
so a 3’ overhang is left. As a result, some genetic material is lost from the ends of the 
chromosomes with each cell division [82]; this is called the ‘end-replication problem’. 
Once the telomeres have been eroded to a certain level (the Hayflick limit [84-86]), the 
cell is prevented from dividing further and apoptoses. Stem cells contain the telomere-
lengthening enzyme telomerase [87, 88], which can also be upregulated in activated T 
cells [89]. This can repair the telomeres via an RNA template [90] and hence allow the 
cell to divide more times or even indefinitely [91]. However, telomerase is turned off 
when T cells become highly differentiated [92, 93], which limits their proliferative 
capacity. 
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Table 1.1. Changing phenotype with increasing differentiation of T cells 
Phenotype  Naïve 
Central 
memory 
Effector 
memory 
CD45RA 
Memory 
References 
CD45RA  +++  -  -  +++  [64-67] 
CD45RB  +++  +++  +  +  [64, 65] 
CD45RO  -  +++  +++  -  [64, 65, 67] 
CD28  +++  ++ 
+ (CD4) 
- (CD8) 
+/-  [64, 66-68] 
CD27  +++  ++ 
- (CD4) 
+ (CD8) 
+/-  [64-66] 
CCR7  +++  ++  -  -  [64, 66] 
CD62L  +++  +++  +  +  [64, 94] 
LFA-1  -  +++  +++  +++  [95, 96] 
CD95  -  +++  +++  +++  [97] 
CTLA-4  +++  ++  ++  +  [98, 99] 
PD-1  +  +++  +++  ++  [100, 101] 
KLRG-1  +  ++  ++  +++  [102, 103] 
BCL-2  +++  ++  +  ++ 
[94, 95, 97, 
104] 
Telomere 
length 
+++  ++  +  ++  [95, 105] 
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Figure 1.2. The end-replication problem, telomeres and the Hayflick limit.
The linear character of eukaryotic DNA means that DNA polymerase cannot replicate each 
chromosome to its very end. 
DNA polymerase can only replicate DNA in a 5’
continuously (the leading strand) while the other, lagging, strand is replicated in short st
called Okazaki fragments, which are subsequently ligated together. 
unable to replicate to the very end of the strand, resulting in a gradual shortening of the genetic 
material (D and E). Repeating telomeric repeats protect the
been eroded to a particular degree, the cell is unable to proliferate further: this is known as the 
Hayflick limit.
 
replication problem, telomeres and the Hayflick limit.
The linear character of eukaryotic DNA means that DNA polymerase cannot replicate each 
chromosome to its very end. A. Paired DNA strands run in opposite directions, 5’
DNA polymerase can only replicate DNA in a 5’-3’ direction. As a result one strand is replicated 
continuously (the leading strand) while the other, lagging, strand is replicated in short st
called Okazaki fragments, which are subsequently ligated together. C. DNA polymerase is 
unable to replicate to the very end of the strand, resulting in a gradual shortening of the genetic 
). Repeating telomeric repeats protect the coding DNA but after these have 
been eroded to a particular degree, the cell is unable to proliferate further: this is known as the 
26 
replication problem, telomeres and the Hayflick limit. 
The linear character of eukaryotic DNA means that DNA polymerase cannot replicate each 
Paired DNA strands run in opposite directions, 5’-3’ and 3’-5’. B. 
3’ direction. As a result one strand is replicated 
continuously (the leading strand) while the other, lagging, strand is replicated in short stretches, 
DNA polymerase is 
unable to replicate to the very end of the strand, resulting in a gradual shortening of the genetic 
coding DNA but after these have 
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Migration 
Naïve T cells are known to circulate in the blood and lymphatic system, homing 
preferentially to the lymph nodes. However, once activated, T cells upregulate specific 
receptors that allow them to home to inflamed tissue, exiting the bloodstream at the 
appropriate site and following a gradient of chemokines to the precise area of 
inflammation [106]. 
 
Transendothelial migration 
In order to pass from the bloodstream to the tissue, leukocytes must cross the barrier 
posed by the wall of the blood vessel, composed of a continuous layer of endothelial 
cells. Migration through endothelium is a multistep process, involving rolling of the cell 
along the endothelial surface, firm adhesion to the blood vessel wall and migration of 
the cell through the endothelial layer, a process termed diapedesis [107] (see Figure 
1.3). This process has been extensively studied with respect to both lymphocytes and 
granulocytes but will be discussed here specifically in the context of T cell migration. 
 
The first stage of T cell migration through endothelium involves the cell rolling along the 
vessel wall, forming transient attachments which are formed rapidly and break as the 
cell moves away, but serve to slow the cell down against the shear force of the blood 
flow [106, 108]. These attachments are mediated by the interaction of selectins with 
their ligands; the binding sites for selectins are carbohydrate moieties, including sialyl-
Lewis
X [108, 109]. There are three selectins involved in leukocyte rolling: L-selectin 
(CD62L), P-selectin (CD62P) and E-selectin (CD62E) [109-112]. L-selectin is 
expressed by the leukocytes themselves, whereas E-selectin is expressed on 
endothelial cells only when activated by, for example, IL-1 or TNF [113]. P-selectin is 
stored in secretory granules located in the cytoplasm of endothelial cells and platelets 
and is cycled to the cell membrane on activation of the cells [114]. Its synthesis is also 
increased by some inflammatory mediators such as LPS (lipopolysaccharide) [115]. 
 
L-selectin is able to bind a number of different ligands, including CD34 [116] and the 
mucosal vascular addressin MadCAM1 [117]. Ligands for L-selectin, including CD34, 
are constitutively expressed by endothelial cells in high endothelial venules, which run 
through lymph nodes, Naïve cells have high expression of L-selectin (see Table 1.1); 
this allows them to home to secondary lymphoid organs for priming [118]. The ligands 
are also, however, upregulated on endothelial cells at sites of inflammation [119]. P-
selectin and E-selectin bind ligands expressed on the surface of the T cell; in the case Chapter 1. Introduction 
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of E-selectin, this is known to include cutaneous lymphocyte antigen (CLA) [120, 121] 
and CD66 [122], an inhibitory receptor upregulated after T cell activation [123]. P-
selectin’s ligands include PSGL-1 [116]. 
 
Integrins are responsible for the next step in T cell migration: firm adhesion of the cell 
to the endothelial lining [113]. Integrins are protein dimers, composed of an α-chain 
and a β-chain. Although 18α and 8β subunits have been discovered in mammals [124], 
the integrins involved in T cell migration are largely either in the β2 class – for example 
LFA-1 (leukocyte function-associated antigen-1; αLβ2 integrin), Mac-1 (αMβ2 integrin) 
or αdβ2 integrin, or α4 class – for example α4β7 and VLA-4 (very late antigen-4; α4β1 
integrin) [124]. Crucial interactions include those of LFA-1 with its ligands ICAM-1 or 
ICAM-2 in the high endothelial venules, and α4 integrins binding to VCAM-1 or 
MadCAM-1 in blood vessels in inflamed tissue [113]. Integrins can also mediate rolling, 
under low-shear conditions [114]. 
 
Integrins on resting T cells are normally in an inactive, ‘bent’ formation. However, when 
the T cell becomes activated, the integrin receives signals from within the cell that 
cause it to acquire a new, extended formation that is able to bind ligands, albeit with 
only intermediate affinity. This is called ‘inside-out’ signalling [124, 125]. The integrin, 
on interaction with its ligand, can then alter its conformation again to become a high-
affinity form (‘open’ conformation) [126]. When the integrin binds its ligand, the T cell 
comes to a stop, firmly bound to the endothelium. 
 
The importance of the above ligand-receptor interactions to T cell migration and the 
consequent functioning of the immune system is underlined by the phenotypes of the 
individuals in whom they are defective. Problems with the early steps of T cell 
transmigration result in an immune disorder termed leukocyte adhesion deficiency 
(LAD), which can take several forms. LAD I results from impaired expression or 
function of the β-chain of the αβ integrins, such as LFA-1 [127]; this form of LAD results 
in moderate to severe immunodeficiency, as T cells and other leukocytes cannot 
mediate firm adhesion, a step required in order to transit through the blood vessels. 
LAD II results from a lack of fucosylated selectin ligands and leads to a less severe 
immunological deficit due to impaired leukocyte rolling [128]. A third type of LAD, LAD 
III, is a disorder whereby individuals have faulty inside-out signalling and hence cannot 
activate their integrins to reach a high-affinity state in response to signals [129]; 
patients with this rare disorder suffer recurrent infections and profound leukocytosis Chapter 1. Introduction 
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[130]. The severity of these disorders indicates that successful leukocyte migration is 
necessary for the proper functioning of the immune system. 
 
The final step in the process of transendothelial migration is diapedesis, in which the T 
cell passes through the endothelial monolayer lining the blood vessel [107]. Initially it 
was thought that cells could only pass through the junctions between endothelial cells 
(para-cellular transmigration); however, more recent studies have provided evidence 
suggesting that transcellular diapedesis – in other words, migration through the 
endothelial cells themselves – is a common phenomenon [131, 132]. However, before 
either para-cellular or trans-cellular migration can occur, migration along the 
endothelium must first take place in order to find sites permissive to the passage of the 
cells. Before initiating migration, therefore, T cells migrate along the surface of the 
endothelium [133] to find an appropriate site, which tends to be either a junction 
between endothelial cells or a region of the endothelial cell away from the nucleus: 
cells cannot migrate at the site of the nucleus [132]. The T cell is thought to extend 
podosomes to ‘probe’ the endothelium in order to locate an appropriate site [134]. 
Adhesion receptors are thought to be crucial for both para-cellular and trans-cellular 
migration to occur [135], particularly ICAM-1, VCAM-1 and LFA-1. 
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Figure 1.3. Transendothelial migration by T cells.
A. T cells travel through blood vessels under significant shear force. In order to exit the vessel 
and pass through the endothelium to the tissue, they follow a multistep process initiated with 
rolling along the endothelial surface, mediated by selectins. 
as a result of integrins interacting with their ligands. Finally, the T cell can pass through the 
junctions between endothelial cells or the endothelial cells themselves in a process called 
diapedesis, before travelling thr
migration. E-, P- and L-
specific chemokines, activate integrins to initiate firm adhesion.
 
Figure 1.3. Transendothelial migration by T cells. 
T cells travel through blood vessels under significant shear force. In order to exit the vessel 
and pass through the endothelium to the tissue, they follow a multistep process initiated with 
rolling along the endothelial surface, mediated by selectins. This is followed by firm adhesion, 
as a result of integrins interacting with their ligands. Finally, the T cell can pass through the 
junctions between endothelial cells or the endothelial cells themselves in a process called 
diapedesis, before travelling through the tissue. B. A selection of molecules involved in T cell 
-selectin mediate rolling; chemokine receptors, once bound by their 
specific chemokines, activate integrins to initiate firm adhesion. 
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Chemokines 
Chemokines are molecules that help to direct the migration of T cells and other 
leukocytes to particular tissues. They and their receptors are named according to the 
pattern of cysteine residues in the chemokines: C, CC, CXC or CX3C [136], with the C 
standing for cysteine and the X for a different amino acid. There are around 50 different 
chemokines and 20 different receptors in humans [137], although not all these 
receptors are expressed by T cells. In addition to being classified according to their 
structure, they can be divided into inflammatory and lymphoid, or homeostatic, 
chemokine receptors [106, 138]; inflammatory chemokines direct cells to sites of 
inflammation, whereas lymphoid chemokines are constitutively present in lymphoid 
organs, maintaining normal lymphoid traffic [106, 138]. 
 
Chemokines are central to the activation of integrins during T cell (and other leukocyte) 
migration, between the rolling and firm adhesion steps [113] (see Figure 1.3B). They 
are tissue-specific molecules secreted by the endothelium, which bind specific 
receptors on the leukocyte. Table 1.2 shows a selection of chemokines, their receptors 
and the tissues to which they direct leukocyte homing. On binding of the chemokine to 
its surface receptor (outside-in signalling), signals within the cell direct the integrin to 
alter its conformation to a more high-affinity shape (inside-out signalling), so that it can 
bind strongly to its ligand and allow the T cell to adhere to the endothelium. In addition, 
after crossing the endothelial barrier, a chemokine gradient continues to direct the 
migrating T cell towards the site of inflammation [138]. 
 
Lymphoid chemokines include CCL19 and CCL21 [139], which bind the chemokine 
receptor CCR7; this is constitutively present on naïve T cells and on central memory 
cells [40, 138], allowing them to circulate via the lymph nodes. CXCR5 is also a lymph 
node-homing chemokine receptor, binding to the follicular-compartment-expressed 
chemokine CXCL13, but is expressed by a specialised subset of helper T cells, 
follicular B Th cells [138]; these provide help for antibody production by B cells [140]. 
CXCR4 is also highly-expressed on naïve cells, allowing entry to high endothelial 
venules (HEVs) and hence the lymph nodes, as well as the bone marrow [141]. 
 
Once primed, T cells upregulate chemokine receptors that allow them to migrate to 
specific tissues. Skin-homing T cells express a number of different chemokine 
receptors which co-operate to direct the cell to cutaneous tissue. Among the most 
prominent are CCR4, expressed by all CLA+ T cells [138] and CCR10 [142], the 
ligands for which have been found on both inflamed and uninflamed cutaneous Chapter 1. Introduction 
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endothelium [143, 144]. CCR5 has been suggested to direct homing to the liver [145] 
and CCR9 to the gut, since its ligand CCL25 is expressed in the small intestine [146]. 
Chemokines have been implicated in a number of diseases. Multiple sclerosis (MS), a 
disease in which the myelin of the nervous system is destroyed by T and B cells, has 
been suggested to be abrogated by injection of neutralising antibodies against CCL3 
[147]. Studies have also found an accumulation of monocytes bearing CCR5, a CCL3 
receptor, and CCR1 in the CNS of MS patients [148]. CCR1 has been linked to a large 
number of inflammatory disorders, including MS, rheumatoid arthritis and kidney 
disease [137], and high levels of CCL3 compared to CCL4 have been implicated in the 
development of insulitis and diabetes [149]. Hence, chemokine antagonists are 
currently much-investigated as potential therapeutic tools [150]. 
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Table 1.2. Chemokines and their receptors 
Chemokine receptor  Ligand(s)  Associated tissue(s)  Cell type 
CCR1 
CCL3 (MIP-1α), 
CCL5 (RANTES), 
CCL7, CCL13, 
CCL14, CCL15, 
CCL16, CCL23 
CNS 
monocytes, mast 
cells 
CCR4 
CCL17 (TARC), 
CCL22 
skin 
effector T cells, 
Tregs, mast cells 
CCR5 
CCL3 (MIP-1α), 
CCL4, CCL5 
(RANTES), CCL8, 
CCL11, CCL14, 
CCL16 
liver, CNS 
effector T cells, 
monocytes, mast 
cells 
CCR7  CCL19, CCL21  lymph node 
naïve T cells, 
central memory T 
cells 
CCR9  CCL25 (TECK)  gut 
effector T cells, 
pDCs 
CCR10 
CCL27 (CTACK), 
CCL28 
skin  effector T cells 
CXCR4  CXCL12 (SDF-1α) 
lymph nodes, bone  
marrow 
naïve T cells, 
central memory T 
cells, mast cells Chapter 1. Introduction 
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1.2 Peripheral regulation of the immune response 
Central mechanisms exist to prevent the escape of autoreactive T cells generated in 
the thymus. Developing lymphocytes encounter MHC presenting self-antigen on the 
surface of cells in the medulla of the thymus and their fate is determined by the 
strength of their reaction to it: too strong and they are deleted, as they risk generating 
autoimmune responses [52, 151]. This mechanism is not fail-safe, however, and 
autoreactive T cells do occasionally escape the thymus to circulate in the periphery 
[152]. 
 
To protect against inappropriate activation, T cells are therefore inherently difficult to 
activate, as discussed in 1.1.1. Cell-intrinsic regulatory mechanisms include the 
upregulation of inhibitory receptors with increasing differentiation and the development 
of anergy if the correct activation signals are not received in full [58]. Apoptosis also 
plays an important role – for example, in the case of activation-induced cell death 
(AICD) [153, 154]. 
 
A further layer of regulation is provided in the periphery by a subset of CD4 T cells with 
immunosuppressive function: regulatory T cells, or Tregs. This prevents autoimmune 
responses from taking hold, and also guards against immunopathology generated as a 
result of valid immune responses continuing out of control [155, 156]. These cells are 
termed regulatory T cells, and can either exit the thymus as suppressive FOXP3+ cells 
[157-160] or are generated in the periphery. Conventional T cells can be induced to 
express FOXP3 [77] or to become other subsets of regulatory T cells that do not 
express FOXP3, such as Tr1 and Th3 cells [161, 162]. 
 
1.2.1 Cell-intrinsic peripheral regulation mechanisms 
In order to prevent aberrant activation and damage to self tissue, responder T cells, 
both CD4+ and CD8+, have a number of in-built mechanisms to regulate their 
activation. First, if a T cell receives a TCR signal without associated costimulation, it 
may enter a state of anergy [58]. Anergic cells are unresponsive: they do not proliferate 
or release cytokines such as interleukin-2 (IL-2) [163], although addition of large 
quantities of this cytokine can break anergy induced in vitro or in vivo [164, 165]. An 
alternative to anergy is death. Previously-expanded T cells, when restimulated in the 
absence of costimulation, undergo activation-induced cell death (AICD) [153, 154]. 
Several different proteins can mediate AICD, including CD95L (Fas ligand). The 
receptor for CD95L, CD95, is expressed on all T cells; they upregulate CD95L after Chapter 1. Introduction 
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activation. Binding of CD95L to its receptor causes caspase activation and apoptosis in 
the cell expressing CD95 [166]. TNF is also able to induce apoptosis after activation 
[167]. These mechanisms serve to limit the T cell response at its peak and to bring it to 
an end. There is an additional role for apoptosis in the peripheral regulation of T cell 
responses: that of death by neglect [168], or activated cell-autonomous death (ACAD). 
This is thought to result from cytokine deprivation or lack of costimulation, leading to 
low levels of the anti-apoptotic factor Bcl-2 and consequent apoptosis [169]. 
 
In humans, but not mice, activated T cells upregulate MHC class II on their surface. 
This allows them to present antigen to each other (a process called T:T presentation) 
[170, 171]. Although activated T cells have been reported to express B7 costimulatory 
molecules as well as MHC class II [170, 172], T:T presentation has been found to lead 
to anergy of responding T cells [170, 171]. This could be another way of ensuring that 
immune responses involving large infiltrates of activated T cells do not become 
uncontrolled and damaging. 
 
Many costimulatory receptors present on the surface of naïve T cells are 
downregulated by more differentiated cells. For example, CD27 is lost after activation 
of CD4+ T cells, followed by CD28. (CD8+ T cells, however, downregulate CD28 first.) 
These two costimulatory receptors bind ligands expressed by the APC: CD28 binds 
B7.1 (CD80) and B7.2 (CD86) [59], whereas CD27 binds CD70 [173]. However, more-
differentiated cells, which have lost these two receptors, can still receive costimulatory 
signals through other receptors such as OX40 and 4-1BB [174, 175]. 
 
As well as the downregulation of costimulatory receptors, there are addition cell-
intrinsic checks on activation that become more prevalent as T cells differentiate. 
CTLA-4 is an inhibitory surface receptor which competes with CD28 for CD80 and 
CD86 binding [59], and has been reported to interact with the intracellular phosphatise 
SHP-2 [176], making it an effective inhibitory receptor. CTLA-4 expression has been 
shown to increase with age [177, 178], as the T cell pool in general becomes more 
differentiated. In addition, programmed death-1 (PD-1) expression increases in 
response to chronic stimulation, for example from persistent viruses [179], along with 
KLRG-1, another inhibitory receptor [102, 103]. These are likely to be extra safeguards 
against highly-differentiated, highly pro-inflammatory CD4 or cytotoxic CD8 T cells 
becoming activated inappropriately. 
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1.2.2 Regulatory T cells 
Cell-extrinsic regulation provides another layer of peripheral regulation and is mediated 
by specialised subsets of T cells. 
 
FOXP3+ natural Tregs 
Identification 
The existence of a regulatory subset of T cells was first postulated in the 1970s [180], 
initially termed ‘suppressor cells’. In the absence of firm identification of these cells, 
however, they fell out of favour until 1995, when Sakaguchi and colleagues identified a 
subset of cells with suppressive function constitutively expressing the α-chain of the IL-
2 receptor, CD25 [181]. This marker was originally thought to be expressed only by 
activated cells, but resting cells with the marker extracted from the peripheral blood of 
mice were shown to be anergic in vitro and to have suppressive function. These cells 
were subsequently shown to be present in humans as well [182, 183], although due to 
the more continuous spectrum of CD25 expression among peripheral blood T cells in 
humans, in this case they are specifically referred to as CD25
hi cells [182]. 
 
FOXP3 
FOXP3 is a transcription factor, the human orthologue of the murine protein Scurfin 
[184-186]. Mutations of the gene Foxp3 in mice, where the resulting gene is non-
functional, cause a systemic autoimmune disease known as scurfy; loss-of-function 
mutations of the human FOXP3 gene are known to lead to a similar syndrome known 
as IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome), 
which is characterised by lymphoproliferation, neonatal IDDM (insulin-dependent 
diabetes mellitus) and eczema, among other symptoms [184, 185]. FOXP3 expression 
was subsequently found to be crucial to Treg function [157-159]. 
 
One of the major characteristics of regulatory T cells, in addition to their ability to 
suppress activation of other cells, is their in vitro anergy [187]. FOXP3 is known to 
suppress transcription of the Il-2 gene via interactions with NFAT (nuclear factor of 
activated T cells) [188] and in the same way to upregulate the inhibitory surface 
molecule CTLA-4 and the α-chain of the IL-2 receptor, CD25. It has also been 
postulated to interact with CREB and NF-κB [189], as well as AKT [190] to mediate 
Treg behaviour. Interactions between FOXP3 and AML/Runx1 have also been shown 
to inhibit IL-2 production and are potentially contributory to suppressive activity [191]. 
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FOXP3 is the most reliable Treg marker discovered to date in humans. Its expression 
in CD4+ T cells in non-inflammatory environments correlates closely with suppressive 
function, more so than the original Treg identifier, CD25 [160, 192]. Although its 
expression seems entirely limited to Tregs in mice [157-159], FOXP3 has been shown 
to be upregulated by human conventional CD4+ T cells when they are stimulated in 
vitro [193]; most studies have found, however, that this does not confer suppressive 
capacity on the activated cells [194-196].  However, ectopic expression of FOXP3 
confers suppressive capability on conventional, responder, CD25- T cells from both 
mice and humans [157, 158, 160, 197, 198]. 
 
Other natural Treg markers 
Tregs have been described as having an ‘activated’ phenotype [199], constitutively 
expressing markers such as CTLA-4 [59, 160], GITR [200, 201] and HLA-DR[202], all 
normally seen only on activated CD4+ T cells (see Table 1.3) [203-205]. The search for 
a defining Treg marker is ongoing; many have been proposed, such as neuropilin-1 
[206], and LAP [207-209], although the former is not Treg-specific in humans [210] and 
the latter is present specifically on a subset of Tregs, not the whole Treg population 
[207, 211]. The IL-7 receptor α chain, CD127, is expressed at a constitutively low level 
by Tregs, whereas responder CD4+ T cells express a reasonably high level [212, 213]; 
however, immediately upon activation, responder T cells transiently downregulate 
CD127 as well [214]. CD39 has also been suggested to identify Tregs [215, 216] but is 
also upregulated on activation [217]. 
All of the above, combined with the upregulation of FOXP3 by conventional T cells on 
activation, makes regulatory T cells difficult to identify in an inflammatory environment. 
However, more markers are continually being postulated; recently, it emerged that a 
promoter region of the FOXP3 gene (referred to as the Treg-specific demethylated 
region, or TSDR) is demethylated specifically in FOXP3+ regulatory T cells [218]. It is 
methylated in conventional cells and remains so even when, on activation, they 
transiently upregulate expression of FOXP3. The TSDR therefore looks like a 
potentially useful marker for identifying true Tregs; however, in order to analyse 
methylation status, the cells must be purified, something not practical for many studies. 
For cells isolated from or investigated in a noninflammatory environment, FOXP3 
remains by far the most reliable marker for Tregs [192].  
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Table 1.3. Treg markers 
Marker  Expression 
Similar expression 
on activated 
responders? 
References 
FOXP3  high  yes, transiently  [158, 192-194] 
CD25  high (bright)  yes  [182, 183, 200] 
CD39 
constitutive (50-
80%) 
yes  [215-217] 
CD127  low  yes  [212-214] 
CTLA-4  constitutive  yes  [59, 204] 
GITR  constitutive  yes  [200, 201, 205] 
HLA-DR  constitutive  yes  [202, 203] 
LAP (membrane-
bound TGF-β) 
activated subset  no  [207, 208, 211] 
Neuropilin-1  constitutively high  yes  [206, 210] 
TSDR  demethylated  no,methylated  [218] 
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Generation and maintenance 
 CD4+CD25
hiFOXP3+ ‘natural’ regulatory T cells [219] are known to be suppressive as 
soon as they exit the thymus as naïve cells [220, 221] and have been proposed to be 
self-reactive cells that escape deletion in the medulla [56, 222]. Notably, 
thymectomised, TCR-transgenic, RAG-deficient mice lack regulatory T cells altogether 
[158, 223], implying that TCR signalling in the thymus is crucial to their development. 
 
When FOXP3+ cells initially exit the thymus, they express the long CD45 splice variant 
CD45RA. In cord blood, almost all Tregs are CD45RA+ [220], but in human adults 90% 
of Tregs have a memory (CD45RO+) phenotype [183, 224]. CD45RA+ regulatory T 
cells are, however, detectable in small numbers throughout adult life into old age [220, 
221]. They are known to be suppressive and to express FOXP3, although at lower 
levels than CD45RO+ Tregs [225]. They may also potentially be used therapeutically, 
as they are expandable in vitro without losing either expression of FOXP3 or their 
suppressive capability – an attribute that is apparently lacking in their CD45RO+ Treg 
counterparts [226]. These expanded Tregs may then be transfused to block 
inappropriate immune activation, for example in response to transplants. 
 
However, although Tregs are initially generated in the thymus, they may develop from 
other sources in the periphery [227, 228]. CD45RO+ Tregs in humans have been 
shown to divide very rapidly and to have short telomeres [228] and so without regular 
input of naïve cells from the thymus their numbers might be expected to decline rapidly. 
Tregs have nevertheless been shown to be stable in number, and even to accumulate, 
in aged individuals, whether humans or mice [229-231]. This observation has led to 
suggestions that they may be converted from peripheral, non-regulatory, CD4+ 
memory T cells [228]. A number of potential mechanisms for this conversion have been 
postulated by experiments performed in vitro, including via the influence of retinoic acid 
[232-234], TGF-β and IL-2 [77, 78, 235] and oestrogen [236]. 
 
The relative contribution in vivo of thymic compared to peripherally-converted Tregs is 
still a matter of debate. However, conversion of responder T cells to Tregs has been 
demonstrated in vivo under a number of conditions. Liang and co-workers [237] found 
that CD4+CD25- cells acquired CD25 and FOXP3 expression and a regulatory 
phenotype when transferred into normal, non-lymphopaenic mice, provided B7 was 
expressed in the recipients. Other studies have also reported induction of regulatory T 
cells in vivo, including experiments supporting the role of TGF-β [238], Treg induction 
as a result of expression of a G-protein receptor [239] and studies suggesting a role for Chapter 1. Introduction 
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thymic exosomes [240]. Additionally, low quantities of peptide administered to mice 
induced a population of suppressive CD4+CD25+ regulatory T cells [241]. 
 
Function 
Natural Tregs exert dominant tolerance over responder T cells – defined as tolerance 
which can be transferred into another host [242]. They suppress proliferation and 
production by responders of proinflammatory cytokines such as interferon-gamma 
(IFN-γ) and IL-2 [187, 243]. The precise mechanism by which natural Tregs exert their 
inhibition is still a matter of some debate. Their suppressive effects can be detected via 
in vitro suppression assays, where they require cell-cell contact with their target 
responder cells in order to suppress their activation, as transwell experiments have 
demonstrated [187, 244, 245]. 
 
The role of cytokines in Treg function is not entirely clear. Numerous studies have 
suggested  that IL-10 and TGF-β are not required for suppression by Tregs in vitro 
[159, 187, 246] but a requirement for these cytokines cannot be entirely ruled out in 
vivo, following experiments performed in mice. Powrie and coworkers found that colitis, 
suppressed by regulatory T cells, was restored following injection of anti-TGF-β 
antibodies [247]. A more recent study by Ring et al showed that anti-IL-10 antibodies 
abrogated the ability of Tregs to suppress tissue inflammation [248]. Additionally, 
surface-bound TGF-β, whether in its active or inactive (LAP) form, has been implicated 
in FOXP3+ Treg-mediated suppression [207, 208, 211]. IL-35, a member of the IL-12 
cytokine family, has also been suggested to play a role [249, 250]. Another proposed 
mechanism is that Tregs act to ‘soak up’ growth factors such as IL-2 [251], although 
why cell contact should be required for such a mechanism to function is not clear. It 
has, however, been suggested that Tregs may require proximity to their target cells 
rather than direct contact [250]. 
 
There is strong evidence to suggest that CTLA-4 is required for Treg function, perhaps 
even more than FOXP3 [252, 253], although even so it has not been universally found 
to be essential [254]. CTLA-4 has been suggested to be involved in Treg-mediated 
suppression of APC function by interacting with CD86 and CD80 on activated 
responder T cells or APCs [255] or even downregulation of these costimulatory 
molecules on the antigen-presenting cells [256, 257]. Tregs may also affect APCs by 
preventing their maturation [258]. They have even been suggested to lyse antigen-
presenting cells [259] or to kill responders directly via perforin and granzyme [260]. It is 
probable that no single mechanism holds the key to Treg-mediated suppression: Tregs Chapter 1. Introduction 
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are likely to control different immune responses, in different environments, in different 
ways. 
 
Recent studies have implicated cyclic adenosine monophosphate (cAMP) and 
adenosine itself, both of which can have suppressive effects [215, 216, 261]. 
Pericellular adenosine is suggested to be generated by co-operation of the 
ectonucleases CD39 and CD73, expressed on the majority of Tregs in mice, and to 
function by binding inhibitory A2A receptors on the target cell [215, 216]. Cyclic 
adenosine monophosphate, known to be inhibitory, has been suggested to accumulate 
to high concentrations in the cytoplasm of Tregs. It is then suggested to be transferred 
to target cells through gap junctions formed between the tightly-apposed regulatory cell 
and responder [261]. 
 
Tregs are implicated in the pathogenesis of cancers: they are thought to suppress 
potential immune responses that could otherwise lead to rejection of the tumours [262]. 
As a result, controlling Treg function could be central to future cancer therapy. They are 
also being investigated as potential tools in the treatment of autoimmune diseases 
such as autoimmune type I diabetes[263], systemic lupus erythematosus (SLE) and 
also to prevent transplant rejection [264]. 
 
Induced Tregs 
Two subsets of regulatory T cells which do not express FOXP3 are thought to be 
induced in the periphery, and are able to suppress via release of cytokines: Th3 cells 
and Tr1 cells. 
 
Tr1 cells can be identified by their production of IL-10 [265]. They also express some 
TGF-β and high levels of IL-5, but very little IL-2 and IL-4, as well as being anergic in 
vitro [265]; in this respect they resemble natural Tregs. They do not, however, express 
FOXP3 [266]. They have been shown to be generated in vitro from both murine and 
human responder CD4+ T cells by means of repeated stimulation in the presence of IL-
10 [265] and IFN-α [161] or via the action of immature dendritic cells [267]. In vivo, they 
can also clearly be generated peripherally: they can develop in response to oral 
administration of IL-10 and antigen in mice [268], and intranasal administration of 
peptides has also been shown to induce tolerant T cells that secrete IL-10, with no IL-2, 
also in mice [268]. Vitamin D3, in combination with dexamethasone, is also capable of 
generating Tr1 cells [269]. 
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Tr1 cells have been shown to be important in the gut and to prevent colitis in mice [265] 
and IL-10 has been shown to improve intestinal inflammation in humans [270]. 
Interestingly, some Th1 cells have been shown to produce IL-10 and IFN-γ together 
and may play a role in gut inflammation [271-273]. 
 
Th3 cells are another subset of CD4+ T cell that are antigen specific, with similar T cell 
receptor clonality to Th1 cells, but produce large quantities of TGF-β1 [274]. They, like 
Tr1 cells, are generated peripherally during the course of the immune response [275] 
and can be induced by oral administration of antigen [276] or the administration of 
mucosal proteins [277]. These cells have also been shown to help alleviate colitis in 
lymphopenic mice [277] and TGF-β transgenic T cells can rescue CD25-knockout mice 
from potentially lethal autoimmunity [278], showing that TGF-β is capable of exerting 
strong suppression. 
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1.3 Ageing and the immune system 
The human lifespan has increased dramatically in the last 150 years [279]. Throughout 
this lengthened lifespan, the immune system must be maintained to prevent the aged 
host from succumbing to infectious pathogens. Defects in various immune cell types 
have been reported in aged humans and animals, with the suggestion that even 
haematopoietic stem cells (HSCs), the precursors of all immune cells, may function 
less efficiently in older adults. In a model comparing the ability of old and young HSCs 
to repopulate the bone marrow of irradiated mice, older HSCs were outcompeted by 
the younger stem cells [280]. There is also a significant decline in the number of naïve 
B cells with age, along with an increase in memory B cells and autoreactive antibodies 
[281]. 
 
The innate immune system is also subject to changes with age, with an increase in 
proinflammatory cytokines such as IL-6 and TNF described in the elderly [282]. Innate 
immune cell subsets such as macrophages become less efficient; the total number of 
NK cells increases with age but their cytotoxicity declines [283]. The combination of 
these factors is thought to contribute to a generalised immune decline in aged humans, 
as demonstrated by their reduced response to vaccines compared with the young [284, 
285]. 
 
1.3.1 Ageing and T cells 
T cells are produced in the thymus, and a number of T cell-specific defects are known 
to be associated with age. Thymic tissue is completely functional in neonates, but with 
age this productive tissue is replaced by fat, a process termed ‘involution’; it is initiated 
by 1 year of age in humans [280]. Some functional tissue can still be found in the 
thymus even at advanced ages, but fewer T cells are able to mature in the involuted 
organ [47]. This leads to an accumulation of memory T cells in the periphery compared 
to naïve cells. 
 
Naïve cells are not only present in lower numbers in old individuals compared to 
younger ones, but are also of lower quality than those in the young, showing lower 
responses to antigen [286, 287] and a decreased capacity to provide help [288, 289]. 
Additionally, a study by Haynes et al directly compared the function of memory cells 
generated from young and aged naïve cells. They found that memory cells generated 
from young naïve cells performed better, even a long period of time after their 
generation [290]. The lower fitness of haematopoietic stem cells in the aged may Chapter 1. Introduction 
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contribute to this, although one study of bone marrow precursor cells have found no 
defect in the ability of these cells to generate functional T cells, whether sourced from 
young or old mice[291]. 
 
Memory T cells have shorter telomeres than their naïve precursors [292]. Although the 
telomere-lengthening enzyme telomerase is upregulated upon T cell activation [293], 
the cells gradually lose the ability to induce telomerase activity after repeated 
stimulation [93, 105, 294]. This can have a deleterious effect on the immune capacity of 
aged individuals as their more-differentiated memory T cells are unable to proliferate to 
the same extent as memory cells in the young [295, 296]. 
 
Additionally, persistent viruses such as cytomegalovirus (CMV) and varicella-zoster 
virus (VZV), which causes chickenpox and shingles, are found in a significant 
proportion of the adult population [297, 298]. During a human lifespan they are likely to 
reactivate several times [297, 298], often asymptomatically, but each time generating 
dedicated memory T cells. By advanced ages, individuals infected with CMV are 
thought to have a significantly less diverse, oligoclonal, T cell pool. This more limited 
range of T cell specificities reduces the breadth of possible immune responses and 
hence is thought to contribute to poor immune responses, particularly to new antigens, 
in the old [299, 300]. 
 
1.3.2 The immune risk phenotype 
Elderly individuals infected with CMV have been found to have significantly lower life 
expectancy over two and four-year periods than CMV- individuals. For this reason, 
infection with CMV is one component of the ‘immune risk phenotype’ [301, 302], which 
predicts mortality. Other contributory factors include low numbers of B cells, a low 
CD4:CD8 T cell ratio and high levels of highly-differentiated CD8+ T cells [303], many 
of these characteristics resulting from CMV infection driving the T cell pool towards 
oligoclonality and senescence. These factors together may be expected to confer a 
significantly shorter life-expectancy on the individual affected. 
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1.4 Immunity in the skin 
The skin is a large organ whose surface is largely exposed to the environment, making 
it essential to form an effective barrier against pathogens. It is also a highly accessible 
tissue that is often subject to inflammation, and can be induced to undergo acute 
inflammation by subcutaneous injection of antigen. Chronic inflammation within this 
organ can be monitored by studying individuals with inflammatory skin disorders, such 
as atopic dermatitis (AD). In this study, we investigated a potential role for memory and 
naïve Treg subsets in the pathogenesis of AD. 
 
1.4.1 Skin immune surveillance 
The barrier function of the skin is accomplished by means of a strong surface layer of 
keratin, generated by epidermal cells [304]. However, occasionally the skin barrier is 
breached, and to protect against this the skin is home to resident immune cells [305]; in 
addition, a large proportion of circulating memory T cells (around 30%) express the 
skin-homing adhesion molecule CLA [306], which facilitates their entry into this tissue. 
CCR8 has also been suggested as a skin-specific chemokine receptor [307]. 
 
The skin is a multilayered structure; underneath the barrier layer of keratin at the 
surface lie the epidermis and dermis (see Figure 1.4) [306], each monitored by different 
immune cells. The epidermis is monitored by Langerhans cells, specialised types of 
dendritic cell containing Birbeck granules, which are thought to be involved in 
engulfment [305, 308]. They can also be identified by their expression of Langerin, a 
molecule involved in ligand internalisation. Although fully competent antigen presenting 
cells, Langerhans cells also appear to have the ability to downregulate immune 
responses in certain situations; for example, they present skin self-antigen during the 
steady-state but do not initiate immune responses against self [308]. Keratinocytes are 
also important in immune surveillance, releasing inflammatory cytokines such as IL-1α 
and TNF [306], as well as chemokines to attract leukocytes. They can also express 
MHC class II [309], giving them the capacity to present antigen. 
 
The dermis is largely composed of collagen, secreted by dermal fibroblasts [306]. It 
contains interstitial or dermal dendritic cells [23, 305, 310] which are also professional 
APCs, though less well-characterised than Langerhans cells. They express DC-SIGN 
and function slightly differently from Langerhans cells: Langerhans have been found to 
preferentially induce cytotoxic CD8+ T cells, whereas dermal DCs have been observed Chapter 1. Introduction 
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to induce CD4+ T cells, skewing the immune response towards humoral immunity 
[310]. 
 
Both sets of dendritic cells, on activation, migrate through the dermal lymphatics to the 
draining lymph nodes of the skin, where they present antigen to T cells. Activation and 
consequent maturation of these antigen presenting cells also results in upregulated 
MHC class II, higher levels of costimulation and more efficient antigen processing [311, 
312], to ensure optimal presentation of antigenic peptides to T cells in the lymph node 
and therefore efficient activation and migration of specific T cells to the skin itself. 
Additionally, antigen presentation has been suggested to take place in the skin itself 
during secondary immune responses, initiating T cell proliferation within the tissue 
[313]. 
 
A small number of memory T cells is also present even in noninflamed dermis [306], as 
a result of a very low level of E-selectin expression in dermal venules, and hence these 
cells can respond particularly quickly to a secondary cutaneous infection. FOXP3+ 
regulatory T cells have also been reported in noninflamed, healthy skin [314] and show 
a strong degree of expression of the skin-homing marker, CLA [315].   Chapter 1. Introduction
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4. The structure 
Resident cutaneous immune cells include two different types of dendritic cell: in the epidermis, 
Langerhans cells, and in the dermis interstitial or dermal DCs. Keratinocytes in the epidermis 
also play an important role in cutaneous immunity, having the capacity bo
and to release proinflammatory cytokines. Some CLA+ memory cells are able to traffic into 
uninflamed skin due to low but constitutive expression of E
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also play an important role in cutaneous immunity, having the capacity bo
and to release proinflammatory cytokines. Some CLA+ memory cells are able to traffic into 
uninflamed skin due to low but constitutive expression of E-selectin on dermal endothelium.
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cutaneous immune cells include two different types of dendritic cell: in the epidermis, 
Langerhans cells, and in the dermis interstitial or dermal DCs. Keratinocytes in the epidermis 
also play an important role in cutaneous immunity, having the capacity both to present antigen 
and to release proinflammatory cytokines. Some CLA+ memory cells are able to traffic into 
selectin on dermal endothelium. Chapter 1. Introduction 
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1.4.2 Monitoring cutaneous immune responses in vivo 
It is possible to obtain a ‘snapshot’ of an ongoing cutaneous immune response by 
taking a biopsy of the affected area and cutting thin sections, which can then be 
stained with dyes or fluorescently-conjugated antibodies to highlight cells of interest. In 
order to monitor a secondary cutaneous response, an antigen to which the individual 
has previously been exposed (for example, PPD, a component of the BCG vaccine) is 
injected subcutaneously. A biopsy can be taken at a defined time after induction of the 
response. 
 
However, our group has expanded the list of tools available to scientists investigating 
the in vivo cutaneous response by developing the skin blister technique [313]. 
Previously-encountered antigen, such as the tuberculin PPD, is injected under the skin 
to provoke a secondary immune response. At day 3 or day 7 after the injection, when 
the immune response is ongoing, a blister is formed over the inflamed site by the 
application of negative pressure. The blister is allowed to stay in place for 18 hours, 
during which time cells involved in the immune response pass into the blister fluid. The 
fluid, and cells within it, can then be harvested. This allows cells actively responding in 
an in vivo cutaneous immune response to be extracted and used in functional or flow 
cytometric analyses in the laboratory. 
 
1.4.3 Atopic dermatitis 
Atopic dermatitis is a hypersensitivity disorder also known as atopic eczema [316], 
which has been increasing in prevalence in the developed world [317, 318]. It has been 
reported in up to 20% of children [316, 319] but does not always persist into adulthood 
[318, 320]. It affects primarily the skin, causing widespread inflammation of the tissue, 
with associated itching and lichenification [320, 321]. It has been linked with other 
hypersensitivity disorders, such as asthma [322], although the nature of the link is 
controversial. 
 
Many different factors are known to contribute to the risk of AD development, including 
environmental allergen exposure and infection, and there is also a strong genetic 
component: having one or both parents affected by AD is a major risk factor for the 
development of the disorder in their children [316]. Contributory factors are known to 
include defects in the skin barrier [323], including loss-of-function mutations of filaggrin 
[324], as well as immunologic factors. Langerhans cells and inflammatory myeloid DCs Chapter 1. Introduction 
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have both been identified in AD lesions [321], TLR defects may also contribute [319] 
and T cells are thought to play an important role [324]. 
 
The acute phase of AD is thought to be primarily Th2-mediated, an allergic response 
involving eosinophils, mast cells and antibody responses [320]. There is also thought to 
be some contribution from Th17 cells [76, 325]: these are effector T cells that produce 
high levels of IL-17, promoting inflammation [326].  The chronic phase, however, is 
Th1-dominated[76, 321]. Adding a further level of complication, cytokines released 
from Th2 cells have also been shown to decrease the expression levels of filaggrin 
[324]. 
 
Tregs have long been of interest in relation to allergy development, and are implicated 
in the pathogenesis of atopic dermatitis in particular because a significant proportion of 
IPEX patients, who have mutated, non-functional FOXP3, show eczema-like symptoms 
[184, 185, 327]. However, as yet no conclusive evidence has been found for a Treg 
defect in atopic patients. Although some studies have reported a defect in suppression 
by atopic Tregs [328], or in their numbers in AD skin [329], this has not been a 
universal finding, with others finding equivalent suppression by AD Tregs and 
increased numbers of FOXP3+ cells in AD skin or peripheral blood [330-334]. 
However, in such a multifactorial disease and with the IPEX link, it remains probable 
that there is some Treg defect in at least a proportion of AD patients. 
 
1.5 Aims of project 
Although the regulatory T cell compartment as a whole is relatively well-characterised, 
little is known about the small naïve (CD45RA+) Treg subset and its contribution to the 
regulation of immunity throughout life. Additionally, we speculated that since atopic 
dermatitis is often a childhood condition from which individuals recover in adulthood, 
the naïve Treg pool may be defective in some patients with AD. The aims of this project 
were to investigate: 
 
1.  The heterogeneity of the Treg pool and changes throughout life. 
2.  The migratory patterns of naïve and memory Tregs. 
3.  The role of Tregs in in vivo immune responses in humans. 
4.  A potential role for different Treg subsets in atopic dermatitis. 
 
 Chapter 2. Materials and Methods 
 
50 
 
Chapter 2. Materials and Methods 
 
2.1 Obtaining human samples 
This work was approved by the Ethics Committee of the Royal Free Hospital. 
 
2.1.1 Healthy controls 
Human peripheral blood was obtained from healthy laboratory staff or healthy 
volunteers aged between 20 and 91 years, with a male:female ratio of approximately 
1:1. Blood was collected into syringes containing heparinized beads and processed 
immediately (see 2.3.2). Alternatively, peripheral blood was obtained in the form of 
buffy coats (National Blood Service, Colindale) and processed on delivery. 
 
2.1.2 Patient samples 
Peripheral blood samples from individuals with atopic dermatitis were obtained through 
the Department of Dermatology, Royal Free Hospital. Individuals were aged between 
21 and 54 years with a male:female ratio of approximately 0.6:1. 
 
2.1.3 Bone marrow samples 
Samples of bone marrow and corresponding peripheral blood, from healthy individuals 
donating bone marrow for transplants, were obtained from the Department of 
Haematology, University College London.  
 
2.1.4 Biopsies 
5mm punch biopsies were taken, by a qualified dermatologist, from normal skin or from 
the site of inflammation in patients with atopic dermatitis. The surrounding skin was 
injected with 2% lignocaine/1:80,000 adrenaline local anaesthetic (Astra 
Pharmaceuticals Ltd, Kings Langley, UK) prior to the biopsy. The wound was closed 
with 4/0 Surgpro polypropylene suture (Tyco Healthcare UK Ltd, Gosport, UK). The 
skin was transported as quickly as possible to the lab in sterile saline. 
 
Biopsies were mounted in Cryo-M-Bed (Bright Instrument Company Ltd, Huntingdon, 
UK) on cork disks, orientated so that the epidermis was perpendicular to the cork disk, 
and snap frozen in isopentane (Sigma-Aldrich, Gillingham, Dorset, UK) cooled in a bath 
of liquid nitrogen. The samples were then stored in a freezer at -80°C. 6 m frozen Chapter 2. Materials and Methods 
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sections were cut at -20°C using a Bright 5040 microtome (Bright Instrument Company 
Ltd, Huntingdon, UK) on to poly-L-lysine coated glass slides (Sigma-Aldrich, 
Gillingham, Dorset, UK). Poly-L-lysine coated slides were used in order to promote 
strong adhesion of the skin section to the slide. Two sections were mounted on to each 
slide. The sections were then left overnight to air-dry and fixed in fresh acetone for 10 
minutes, followed by 99% ethanol for 10 minutes. The sections were air-dried for 10 
minutes and then cling film-wrapped and stored until use in a freezer at -80°C. 
 
2.1.5 Skin suction blisters 
Skin suction has previously been shown to result in the formation of a split between the 
epidermis and dermis at the level of the lamina lucida. Suction blisters were induced by 
the application of negative pressure of 25-40kPa (200-300mmHg below atmospheric 
pressure)  via  a  suction  chamber  (Medical  Engineering,  Royal  Free  Hospital,  UK) 
centred  over  the  site  of  testing  for  2-4  hours  using  a  clinical  suction  pump  (VP25, 
Eschmann, Lancing, UK). Skin suction chambers with apertures of 15mm, 12.5mm and 
10mm were used according to the size of the response and skin elasticity.  In all cases, 
the size of suction chamber aperture selected ensured that the whole of the area of 
induration  was  sucked  up  in  to  the  chamber  with  minimal  incorporation  of  normal 
surrounding skin.  
 
Suction  was  applied  at  warm  room  temperature  (~22°C)  until  a  unilocular  blister 
measuring 10-15mm was formed over the site of the skin test.  The blister was then 
protected overnight with a rigid adhesive dressing assembled using a Comfeel plus 
ulcer dressing (Coloplast, Peterborough, UK), a universal top (Sterilin, Fisher Scientific 
UK Ltd, Loughborough, UK), Micropore tape (3M healthcare, Loughborough, UK) and 
Tubigrip bandaging (Seton Healthcare Group plc, Oldham, UK).   
 
Blister fluid was aspirated from the blister at 18-24 hours after induction using a sterile 
23G needle and a 2ml syringe (Tyco Healthcare UK Ltd, Gosport, UK).  The fluid was 
aspirated at the 18-24 hour time point in order to ensure maximal accumulation of cells 
within the blister fluid from the site of antigenic challenge in the skin.  The recorded 
time of sampling was the time from skin injection to blister fluid aspiration.  The volume 
of fluid recovered from the blister was recorded and suspended in 1.5ml conical tubes 
(Alpha Laboratories Ltd, Eastleigh, UK).  The aspirated blister site was dressed with 
Betadine dry powder spray (Seton Healthcare Group plc, Oldham, UK) and a Mepore 
dressing (MoInlycke Health Care Ltd., Dunstable, UK).  Volunteers were advised to Chapter 2. Materials and Methods 
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leave the dressing in place and to keep it dry for 24 hours before removing it and 
leaving the wound open to the air.  The suction cups were dismantled after use and 
disinfected in Barrycidal 36 (Heraeus Instruments Ltd, Brentwood, Essex, UK) for a 
minimum of 24 hours. 
 
The blister fluid was microcentrifuged at 650xg (3000 rpm) for 4 minutes (Microcentaur, 
MSE,  Sanyo)  to  pellet  the  cellular  contents.    The  supernatant  was  removed  and 
aliquotted  in  to  1ml  cryogenic  tubes  (Nunc,  Thermofisher  Scientific,  Roskilde, 
Denmark) and stored at -70°C until analysed.  The blister cell pellet was resuspended 
in 500µl of RPMI 1640(GIBCO, BRL Life Technologies, Paisley, UK) containing 10% 
human AB serum, 100U/ml penicillin, 100µg/ml streptomycin and 2mM L-glutamine (all 
from Sigma Aldrich, Gillingham, Dorset, UK).  
 
2.2 Freezing Samples 
2.2.1 Freezing lymphocytes for further live-cell analysis 
In order to preserve living cells for further analysis, PBMCs were adjusted to 10-
20x10
6/ml in pre-cooled foetal bovine serum (FBS) (Gibco Invitrogen Ltd, Paisley, UK). 
An equal volume of pre-cooled 20% dimethyl sulfoxide (DMSO) (Sigma-Aldrich Ltd, 
Poole, UK) in FCS was added, to give a final suspension of 5-10x106/ml PBMCs in 
10% DMSO/90% FCS. The suspension was then transferred into cooled cryotubes 
(Nalge Nunc International), 1ml per cryotube, and the cryotubes were placed in a 
chilled freezing container (Nalgene Cryo 1°C freezing container). The container was 
stored at -80°C overnight; the cryotubes were then transferred to storage containers 
and kept at -80°C until required. 
 
2.2.2 Thawing lymphocytes 
Frozen lymphocytes were thawed in an excess (10:1) of complete medium warmed to 
37°C. They were immediately centrifuged at 1200rpm for 10 minutes and resuspended 
in complete medium for analysis. 
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2.3 Purification of Lymphocyte subsets 
2.3.1 Peripheral blood mononuclear (PBMC) isolation 
Blood samples were diluted with an equal volume of HBSS (Hanks’ Balanced Salt 
Solution, Gibco Invitrogen) and the diluted blood was layered onto Ficoll Paque (GE 
Healthcare). 20ml diluted blood were layered onto 15ml Ficoll. The layered preparation 
was then centrifuged at 2000rpm for 20 minutes. PBMC at the interface were removed 
by aspiration and washed in HBSS twice: first at 1800rpm for 10 minutes and then at 
1200rpm for 10 minutes, before being counted. 
 
2.3.2 MACS isolation 
This protocol allows the removal or purification of specific subpopulations of leukocytes 
by the addition of small, biodegradable magnetic beads attached to antibodies against 
particular cell surface markers (Miltenyi Biotec, Bergisch Gladbach, Germany). The 
cells are incubated with these beads in a solution of MACS buffer (1x PBS, 2mM 
EDTA, 0.5% BSA). The buffer is degassed before use by placing a loosely-capped 
tube in a vacuum flask. After incubation, the cells are then passed through a column by 
a magnet: the labelled population of cells is immobilised in the column, while the 
unlabelled population passes through to be collected in suspension underneath. The 
immobilised, labelled population can, if required, be isolated by removing the column 
from the magnet and flushing it through with MACS buffer. 
 
The following kits were used (the manufacturer’s protocol was followed, except where 
indicated): 
 
CD4+ microbeads [130-045-101] 
CD4+ T cell isolation kit II [130-091-155] 
CD4+CD25
hi Regulatory T Cell Isolation Kit, human [130-091-301] 
The manufacturer’s protocol was altered as follows: Cells were initially incubated for 10 
minutes at 4°C with MACS buffer (95 l/10
7 cells) and non-CD4 biotin-conjugated 
antibody (5 l/10
7 cells). After this incubation, anti-biotin microbeads were added to the 
mixture (10 l/10
7 cells) and the sample incubated for a further 15 minutes at 4°C. Cells 
were passed through an LD column as instructed by the manufacturer. The run-through 
was washed and the cells counted, then incubated in a solution of MACS buffer 
(80 l/10
7 cells) with anti-CD25 beads from the kit (20 l/10
7 cells), for 15 minutes at 
4°C. Cells were then run through an MS column as instructed by the manufacturer; the 
run-through was incubated with a second round of CD25+ microbeads at the same Chapter 2. Materials and Methods 
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concentration, before being run through a second MS column to obtain pure CD25- 
cells. The immobilised (CD25
hi) cells from the first MS column were flushed directly 
onto another MS column with 2ml MACS buffer and the solution allowed to run through. 
The cells immobilised on this second column were then flushed into a suitable 
container using a further 2ml MACS buffer. 
CD45RA+ microbeads [130-045-901] and CD45RO+ microbeads [130-046-001] 
These were used with the Regulatory T Cell Isolation Kit as an extra step between CD4 
negative selection and CD25
hi positive selection. Cells were incubated with the 
concentrations of beads indicated by the manufacturer, before being run through an LD 
column (hence, CD45RA beads were used to isolate CD45RA-CD45RO+ cells and 
CD45RO beads to isolate CD45RA+CD45RO- cells). 
 
After isolation, cells were washed and resuspended in complete medium for further 
analysis or functional studies. 
 
2.3.3 Cell-sorting 
PBMCs were isolated as described in 2.3.1 and either total PBMCs or cell subsets 
(obtained via MACS as described in 2.3.2) were stained with fluorescently-conjugated 
antibodies against cell-specific markers (see 2.5.1). Cells were then suspended in 
RPMI containing 1% human serum and HEPES (Gibco, Invitrogen) and loaded into 
strainer cap-bearing FACS tubes (BD Falcon). Cells were sorted into serum-coated 
polyethylene tubes using a FACSAria (BD) and were immediately washed and 
resuspended in complete medium. 
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2.4 In Vitro Cell Culture 
2.4.1 Standard cell culture conditions 
Cells were cultured in ‘complete medium’: RPMI containing 2mM L-glutamine, 100U/ml 
penicillin, 100 g/ml streptomycin and 10% human serum (all Sigma-Aldrich). They 
were cultured in 96-well round-bottomed plates (BD Falcon) at a total volume of 
200 l/well in an incubator set to 37°C and 5% CO2. 
 
2.4.2 Measurement of cellular proliferation in vitro 
Cells were stimulated using either T-cell Expander Beads coated with anti-CD3 and 
antiCD28 (Dynal) or plate-bound anti-CD3 (OKT3) in the presence of irradiated APCs, 
in either flat- or round-bottomed 96-well plates. OKT3 was used at a concentration of 
1 g/ml. APCs were either total PBMCs or non-CD4 T cells and were irradiated by 
administration of X-rays to a dose of 40 Grays, then recounted and used at 1:1 with the 
cells being stimulated. After 72 hours’ stimulation, 10 l of 0.0025MBq [
3H]-thymidine 
was added to each well and the plate was incubated for a further 16 hours. Cells were 
then harvested onto glass microfibre filter mats (Wallac, Finland) using a cell harvester 
(Cambridge Technology, Watertown, MA, USA) and counts of incorporated [
3H]-
thymidine were determined using a betacounter (Perkin Elmer, MA, USA). 
 
2.4.3 Suppression assays 
CD4+, CD4+CD25
hi and CD4+CD25- T cells were isolated as described in 2.3.2. 
Culture conditions were as described in 2.4.2 and cell cultures were set up in the 
following combinations: CD4+ alone; CD4+CD25- alone; CD4+CD25- with 
CD4+CD25
hi; CD4+CD25- with further CD4+CD25-; and CD4+CD25
hi cells alone. Cells 
were stimulated with T-Cell Expander Beads in round-bottomed 96-well plates, at a 
concentration of one bead per responder cell. 50,000 of each cell type were used per 
well. To assess proliferation, the cultures were pulsed after 72 hours’ incubation with 
[
3H]-thymidine, as described in 2.4.2. To assess cytokine secretion, responder cells 
were first stained with CFSE (see 2.5.5) to allow for discrimination between responders 
and Tregs. The cells were incubated in the combinations described above, with T Cell-
Expander Beads, for 48 hours and then restimulated with 50ng/ml PMA and 250ng/ml 
ionomycin (both from Sigma-Aldrich, Gillingham, Dorset, UK). After three hours, 
Brefeldin A (BFA; Sigma-Aldrich, Gillingham, Dorset, UK) was added at a final 
concentration of 5 g/ml and the cultures incubated for a further three hours. The cells Chapter 2. Materials and Methods 
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were then stained for cytokine production following the intracellular staining protocol 
(see 2.5.2). 
 
2.5 Flow Cytometry 
Flow cytometric acquisition was performed by three different models of flow cytometer 
for these studies. Sorting was performed on the FACSAria, which contains three lasers 
(488nm, 635nm and 350nm) and is able to detect up to ten different colours. Simple 
flow cytometric acquisition was performed on either a FACSCalibur, which has two 
lasers (488nm and 6500-650nm) and can detect four colours, or a BD LSR 1, which 
has 3 lasers (325nm, 488nm, and 640nm) and can detect six colours. All machines are 
from Becton Dickinson (BD), Oxford. Analysis of acquired data was performed using 
either CellQuest software (BD) or FlowJo software (TreeStar, Inc, OR, USA).  
 
2.5.1 Surface staining by direct immunofluorescence 
Direct immunofluorescence involves the addition to cells of specific antibodies directly 
conjugated to fluorochromes; this is a single-step procedure and does not require the 
addition of further antibodies. Table 2.1 summarises the antibodies used in these 
studies, the optimal concentration of which was determined by preliminary titration. In 
most cases, four- or five-colour protocols were used, which allow the detection of four 
or five antigens simultaneously. This is possible because fluorochromes such as FITC 
and PE are excited at the same wavelength of light, but emit at different wavelengths, 
so all fluorochromes can be detected by the flow cytometer at the same time using 
filters and compensation controls. 
 
For staining, the required cell sample was added to a 5ml FACS tube (BD Falcon) in a 
volume of 100 l. Antibodies were added at pre-titrated optimal concentrations and the 
sample was mixed and incubated at room temperature for 15 minutes. The cells were 
washed in PBSA (Phosphate Buffered Saline in 1% w/v bovine serum albumin and 
0.02% sodium azide) and centrifuged at 1800rpm for 5 minutes, then fixed in 200 l of 
2% paraformaldehyde (PF) in PBS (Phosphate Buffered Saline). Samples were stored 
at 4°C for no more than 24 hours prior to analysis. When conjugated fluorochromes, 
such as PE-Cy7, were used, the antibody-cell mixture was incubated on ice for 30 
minutes rather than at room temperature in order to maintain the stability of the 
fluorochrome. Samples were then washed and fixed in PF as above. In all cases, 
samples were kept on ice while analysis was taking place. 
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Table 2.1. Antibodies used in flow cytometry 
 
 
Type of 
staining 
Antigen  Isotype  Clone  Fluorochrome 
 
Membrane 
CCR4  Mouse IgG1  1G1  PE 
CD4  Mouse IgG1  SK3  PerCP 
CD25 
Mouse IgG1  ACT-1  PE 
Mouse IgG1  2A3  PE-Cy7 
CD31  Mouse IgG1  WM59  FITC & PE 
CD39  Mouse IgG1  A1  FITC 
CD45RA 
Mouse IgG2b  HI100  FITC 
Mouse IgG1  L48  PE-Cy7 
Mouse IgG2b  MEM-56  APC 
CD45RO 
Mouse IgG1  UCHL-1  APC 
Mouse IgG1  UCHL-1  PE 
CD69  Mouse IgG1  L78  PE 
CD73  Mouse IgG1  AD2  PE 
CLA  Rat IgM  HECA-452  FITC 
CXCR4  Mouse IgG2a  12G5  PE 
Isotype control 
Mouse IgG1, 
IgG2a, IgG2b 
Rat IgM 
- 
FITC / PE / 
PE-Cy7 / 
PerCP / APC 
Cytokine 
IL-2  Mouse IgG1  5334  PE 
IL-4  Mouse IgG1  3010.211  PE 
IL-10  Rat IgG2a  JES3-19F1  APC 
IFN-γ  Mouse IgG1  B27  APC 
TNF-α  Mouse IgG1  6401.1111  FITC 
Intracellular 
CTLA-4  Mouse IgG2a  BN13  PE 
FOXP3  Mouse IgG1  3G3  APC 
Ki67  Mouse IgG1  B56  FITC 
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2.5.2 Surface staining for CTLA-4 
CTLA-4 is a molecule that is largely present in the cytoplasm of resting cells and 
routinely cycles between the cytoplasm and cell surface membrane [59, 335]. Surface 
staining protocols for CTLA-4 must be altered as a result of this. Cells to be stained 
with CTLA-4 were initially resuspended in a total volume of 100µl; 10µl of anti-CTLA-4 
were added and the samples incubated for 30 minutes at 37° C. They were then 
washed in PBSA, centrifuged for 5 minutes at 1800rpm and restored to a volume of 
100µl. Other surface antibodies were added and the samples incubated on ice for 30 
minutes, before either being washed as before and fixed in 2% PF, or stained for 
FOXP3 expression (see 2.5.4). In order to stain for total (intracellular and surface) 
CTLA-4 expression, surface staining with the other antibodies was done as in 2.5.1 and 
anti-CTLA-4 antibody was added at the same time as anti-FOXP3 in the FOXP3-
staining protocol, described in 2.5.4. 
 
2.5.3 Intracellular cytokine staining 
In order to detect the production of cytokines by different cell subsets, stimulation (in 
order to initiate cytokine production) and blocking via BFA (to prevent cytokine release) 
were necessary as described in 2.4.3. After 3 hours’ incubation with BFA, cells were 
centrifuged at 1800rpm for 5 minutes, supernatants removed and the cell samples 
resuspended in a volume of 100 l. They were surface-stained for 15 minutes at room-
temperature, as described in 2.5.1. Before the washing step, 100 l of Caltag A solution 
(fixation medium; Caltag Medsystems, Bucks, UK) were added to each tube and the 
mixture vortexed for 15 seconds. Samples were incubated for a further 15 minutes at 
room temperature, then washed in excess PBSA at 1800rpm for 5 minutes. The 
supernatant was tipped off and the tubes dried, before 100 l Caltag B solution 
(permeabilisation medium) were added to each tube, along with pre-titrated volumes of 
fluorochrome-conjugated antibodies against the cytokines being investigated. The 
tubes were vortexed and incubated for a further 15 minutes, before being washed in 
PBSA again and resuspended in 200 l 2% PF for analysis, to be acquired within 24 
hours. 
 
2.5.4 FOXP3 staining 
FOXP3 is a transcription factor, located within the nucleus of cells, and is therefore less 
accessible than cytoplasmic antigens such as recently-translated cytokines. A stronger 
fixation/permeabilisation protocol is therefore required to detect its expression. Staining 
was performed using the antibody and kit from Miltenyi Biotec. The same kit and Chapter 2. Materials and Methods 
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protocol were used to stain for Ki67, another nuclear protein. Up to 10
6 cells were 
resuspended in a total volume of 100 l. They were first surface-stained as described in 
2.5.1, then washed in ice-cold PBS at 1800rpm for 5 minutes. Fix/Perm solution from 
the kit was made up, according to the manufacturer’s instructions, and 1ml added to 
each sample. The tubes were incubated for 40 minutes at 4°C. The samples were then 
washed again in ice-cold PBS, dried and resuspended in 100 l 1x Permeabilisation 
Buffer. A previously-titrated optimal concentration of anti-FOXP3, Ki67 and/or CTLA-4 
antibody was added and the cells incubated for a further 30 minutes at 4°C. The 
samples were washed in permeabilisation buffer and fixed in 200 l 2% PF for analysis. 
They were acquired on the flow cytometer within 24 hours of staining. 
 
2.5.5 CFSE staining 
CFSE (carboxyfluorescein succinimidyl ester; Molecular Probes, Inc) can be used to 
measure proliferation, by staining a population of cells and then acquiring them on a 
flow cytometer after stimulation; as the cells divide, the dye becomes progressively 
diluted and so the green signal detectable by FACS becomes weaker. In this study, 
CFSE was used both to follow cell divisions and also simply to mark populations of 
cells – for example, responder T cells, to distinguish them from the Tregs with which 
they were cultured. 
 
The cell sample to be stained was centrifuged at 1800rpm for 5 minutes and the pellet 
resuspended in warm PBS. An equal volume of warmed, prediluted CFSE in PBS at a 
concentration of 1 M was added, to give a final concentration of 0.5 M, and the 
sample was mixed. The cells and dye were incubated for 13 minutes at 37°C. The 
reaction was stopped by adding FBS to a concentration of 10% and placing the sample 
on ice in the dark. After 10 minutes, the sample was washed at least twice in complete 
medium and then resuspended in complete medium at a suitable concentration for cell 
culture. 
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2.6 Anergy Induction 
2.6.1 Generation of a PPD-specific CD4+ T cell line 
PBMCs were harvested from the blood of volunteers with a strong PPD-specific 
response, and incubated with 1µg/ml PPD at 37° C and 5% CO2. After two weeks the 
cells were restimulated by adding PPD to PBMCs from the same donor, incubating for 
one hour, then irradiating (40Gy) and adding these cells to the culture, This was 
repeated every two weeks for six to eight weeks, after which the cells were assumed to 
be PPD-specific. 
 
2.6.2 Induction of anergy 
PPD-specific CD4+ T cells were incubated with plate-bound 0.05µg/ml, 0.1µg/ml or 
0.5µgml OKT3 overnight (or in plates coated with PBS as a control). Cells were then 
removed from the plates, counted and washed to remove as much debris as possible 
before being phenotyped or used in functional assays. 
 
2.7 Immunohistochemistry 
In order to investigate the presence or absence of T cell populations in the skin, 
sections from biopsies (see 2.1.4) were stained using two layers of antibodies: first, 
antibodies specific for markers on the cells but not conjugated to any fluorochrome 
(Table 2.1). These were followed by fluorochrome-conjugated secondary antibodies, 
which were isotype- and species-specific anti-immunoglobulin. Alternatively, biotin-
conjugated primary antibodies were used, followed by a fluorochrome (Cy3)-
conjugated streptavidin second layer. Table II summarises the antibodies used to stain 
skin sections. 
 
In order to stain the skin samples, slides bearing the sections were first removed from 
storage at -80°C and allowed to come to room temperature in a humidified 
environment. Slides were washed in 1x PBS for 5 mins, after which Protein Block was 
added (DakoCytomation UK Ltd, Ely, UK) and incubated for 20 minutes. The block was 
removed and primary antibodies added, diluted to pre-titrated optimum concentrations 
in 1x PBS. 40 l were added to each section. The slides and antibody were incubated 
at 4°C overnight. Slides were then washed for 10 minutes in the dark; this wash was 
repeated for a further 10 minutes, before the slides were dried and secondary 
antibodies (again diluted to optimum concentrations) were added at 40 l per section. 
The sections and antibody were incubated for 45 minutes at room temperature. The Chapter 2. Materials and Methods 
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slides were washed two further times, for 10 minutes each, and then dried. They were 
mounted using Vectashield with Dapi (Vector Laboratories, Burlingame, CA) and the 
stained sections were stored in the dark at -20°C prior to analysis. They were analysed 
using a Leica DMLB microscope with a 40x objective, in conjunction with a Cool SNAP-
Pro cf Monochrome Media Cybernetics camera and ImagePro PLUS 6.2 software. 
 
To count cells, the five largest infiltrates (or as many large infiltrates as possible if fewer 
than five were available) within each section were selected and positive cells within the 
field of view of each infiltrate were counted by two independent researchers. An 
average was taken for each section.   Chapter 2. Materials and Methods 
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Table 2.2. Antibodies used in immunohistochemistry 
 
Primary/secondary  Antigen  Isotype  Clone  Conjugate 
Primary 
CD4  Mouse IgG1  SK3  Unlabelled 
  Rat IgG1  YNB46.1.8  Unlabelled 
CD8  Mouse IgG1  RPA-T8  Biotin 
CD45RA  Mouse IgG2b  HI100  FITC 
CD45RO  Mouse IgG2a  UCHL1  Unlabelled 
FOXP3  Rat IgG2a  PCH101  Biotin 
Ki67  Mouse IgG1  MIB-1  Unlabelled 
Secondary 
Anti-mouse Ig 
Goat F(ab’)2 
fragment 
- 
AlexaFluor 
488 
 
Goat F(ab’)2 
fragment 
- 
AlexaFluor 
546 
Anti-rat Ig 
Goat F(ab’)2 
fragment 
- 
AlexaFluor 
546 
Streptavidin  -  -  Cy3 
Anti-FITC 
Goat IgG 
(polyclonal) 
- 
AlexaFluor 
488 
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2.8 Migration studies 
2.8.1 Growth and activation of endothelial cells 
Dermal endothelial cells (HDMEC-c dermal microvascular endothelial cells from adult 
dermis; PromoCell, Germany) were cultured in 25cm
2 tissue culture flasks in 
endothelial cell growth medium (PromoCell). When confluent, the cells were removed 
from the flask with trypsin (PromoCell) and plated onto a flat-bottomed 96-well plate 
among as many wells as required (at least six per condition to be investigated). They 
were incubated at 37° C and 5% CO2 until confluent in each well. 24 hours before 
testing migration of T cells, the endothelial monolayers were stimulated with 100ng/ml 
TNF and 100U/ml IFN-γ. 
 
2.8.2 Migration 
The T cell subsets to be investigated were isolated the day before the migration assay 
using MACS technology and incubated overnight, without stimulation, at 37° C and 5% 
CO2. They were then resuspended in serum-free medium (AIM-V; Gibco, Invitrogen) at 
a concentration of 200,000 cells/ml. To perform the migration assays, endothelial 
monolayers were first washed with HBSS, then 100µl of cell suspension was added 
and incubated at 37° C for 2-4 hours. Each condition was repeated 6 times. After the 
requisite time had passed, the plate was placed in a culture chamber (37° C, 5% CO2) 
attached to a Zeiss Axiovert 200M light microscope. Time-lapse videos were obtained 
using a Hamamatsu Orca-ER digital camera and Simple PCI software, with images 
being taken every 10 seconds for 5 minutes. Cells which had migrated and were hence 
under the endothelial monolayer appeared darker and flatter; these were counted, 
along with the unmigrated cells in the field of view, so that the proportion of cells 
migrating after 2 or 4 hours could be estimated. The mean of six repeats was taken. 
 
2.9 Statistics 
Statistical analyses were performed using GraphPad Prism version 4.0 (GraphPad 
Software, San Diego, USA). Student’s t-tests were used to analyse normally-distributed 
data; where data could not be assumed to be normally distributed, either the Wilcoxon 
Matched Pairs test or the Mann-Whitney test were used, depending on whether 
samples were paired or unpaired. Correlations were calculated using Spearman  
correlation calculations. P values are indicated on the majority of graphs with asterisks 
or text: ns (not significant), * (p<0.05), ** (p<0.01) and *** (p<0.001).Chapter 3. Maintenance of human FOXP3+ Tregs throughout life 
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Chapter 3. Maintenance of human FOXP3+ 
Tregs throughout life 
 
3.1 Introduction 
In order to maintain closely-regulated immunity throughout life, the pool of Tregs must 
be sustained over the human lifespan of 8 decades. The majority of Tregs in adult 
humans have a highly-differentiated phenotype, with 90% expressing the memory 
marker CD45RO [224]. Tregs are generated in the thymus, as CD45RA+ cells, but 
numerous studies have demonstrated that they can also be generated in the periphery, 
following conversion of conventional CD4+ T cells into CD45RO+ FOXP3-expressing 
cells with an ability to suppress [77, 78, 232, 235, 236]. There is presently widespread 
debate about the proportion of Tregs in adult humans that have been generated 
thymically compared to the proportion converted peripherally from responder CD4 T 
cells, and it is not yet easy to identify which Tregs have been produced by either 
process. 
 
This study aimed to compare the phenotypic and functional attributes of naïve Tregs 
with the more differentiated CD45RO+ subset in order to further define the 
interrelationship between the two subsets. Recently thymically-produced cells (recent 
thymic emigrants, or RTEs) have been shown to express CD31 in conjunction with 
CD45RA [69] and the prevalence of these cells within the Treg pool was investigated in 
the context of ageing. We also investigated another potential mechanism by which 
regulatory T cells could be generated from conventional CD4+CD25- cells in the 
periphery: anergy induction. 
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Figure 3.1. The proportion of CD4+ cells expressing CD25 to a high level increases with 
age. 
Peripheral blood mononuclear cells were obtained from healthy volunteers aged between 20 and 91, and 
stained directly ex vivo for CD4 and CD25.  Cells expressing the highest level of CD25 were gated and the 
proportion of the total CD4 compartment observed.
was set at the upper limit of CD25 expression in non
calculated after gating on CD4+ cells only.
CD25
hi with age. (n=62) 
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3.2 Changes in the Treg pool with age 
3.2.1 The proportion of CD25
hi cells within the CD4+ T
increases with age 
In order to investigate changes in the Treg pool with ageing, samples of blood were 
volunteers of different ages and peripheral blood mononuclear cells 
(PBMCs) were stained for the Treg markers CD4 and CD25. As shown in Figure 
with age was observed in the proportion of CD4+ cells that were CD25
reg phenotype. In fact, a significant increase of these cells 
(p=0.0132, r=0.3210, n=62). 
B. 
. The proportion of CD4+ cells expressing CD25 to a high level increases with 
Peripheral blood mononuclear cells were obtained from healthy volunteers aged between 20 and 91, and 
for CD4 and CD25.  Cells expressing the highest level of CD25 were gated and the 
proportion of the total CD4 compartment observed. A. Gating strategy for CD25
hi
upper limit of CD25 expression in non-CD4+ lymphocytes. Percentages were then 
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3.2.1 Age-related alterations in proportions of Tregs expressing 
CD45RA and CD45RO 
The composition of the conventional CD4+ T cell pool is known to change with age [64-
68]. Although the Treg pool is maintained in older individuals, it is also likely to undergo 
changes with age in the differentiation status and sources of the cells which compose 
it. To investigate changes in the composition of the Treg pool with age, ex vivo Tregs 
from volunteers of various ages were stained with CD45RO and CD45RA to mark 
memory and naïve cells, respectively. A significant reduction with age in the proportion 
of Tregs bearing a CD45RA+CD45RO- phenotype was observed (Figure 3.2A). This 
was accompanied by a concordant increase in the proportion of Tregs (defined as 
CD4+CD25
hi cells) that was CD45RA- CD45RO+ (Figure 3.2B). 
 
The line between ‘naïve’ and ‘memory’ is blurred with respect to T lymphocytes: 
CD45RA+, naïve T cells can become activated and begin to divide a few times before 
they lose expression of CD45RA [69, 336]. As a result, numerous groups have 
attempted to find a marker that is more specific for truly naïve T cells – i.e. which have 
recently exited the thymus and have not encountered cognate antigen. Recent studies 
have suggested that the adhesion molecule, CD31 (also known as PECAM-1, Platelet 
Endothelial Cell Adhesion Marker-1) may, when expressed on CD45RA-bearing cells, 
identify these RTEs: CD45RA+CD31+ CD4 T cells have been found to have longer 
telomeres, more TRECS and functions indicative of a less-differentiated phenotype 
than CD45RA+CD31- CD4+ cells [69, 70]. 
 
The proportion of Treg cells with an RTE phenotype and the proportion of CD45RA+ 
Tregs expressing CD31 were therefore also investigated. Although the proportion of 
RTE cells within the total Treg pool was reduced with age, the proportion of CD45RA+ 
Tregs expressing CD31 did not change significantly (Figure 3.2D), although there was 
a trend towards a decrease in the proportion of this subset. The continued presence of 
a significant proportion of CD31+ naïve Tregs in most donors, even in old donors, 
suggests that a small proportion of Tregs are likely to come directly from the thymus 
throughout life. This raises the possibility that thymically-derived Tregs may support the 
Treg pool throughout adult life, perhaps by extensive division. 
   Chapter 3. Maintenance of human FOXP3+ Tregs throughout life
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3.3 Naïve and memory Tregs proliferate at different 
rates 
Previous work by our group demonstrated that human Tregs have a very high rate of 
turnover in vivo as well as short telomeres and susceptibility to apoptosis [228]. Naïve 
Tregs, however, are less differentiated and have much longer telomeres, equivalent to 
telomere lengths in naïve responder T cells [221]. If CD45RA+ Tregs also proliferate at 
a high rate, they may be able to support Treg numbers, even during later life after 
thymic involution. We therefore extended our earlier work to investigate the proliferative 
rates of the naïve and memory subsets within the Treg pool. Our previous studies used 
deuterated glucose (6,6-D-glucose), following its incorporation into and loss from the 
DNA of dividing cells. The small size of the naïve subset prevented us from using the 
deuterated glucose method in this case. Instead, we used a flow cytometry-based 
method, staining cells with fluorochrome-conjugated antibodies against the nuclear 
marker of proliferation, Ki67. This protein is expressed in the nucleus at all stages of 
the active cell cycle [337, 338]. 
 
3.3.1 Proliferation among CD45RO+ and CD45RA+ Tregs 
As shown in Figure 3.3A, Ki67 expression was found to be highly prevalent among 
CD45RO+ Tregs, with 18%, on average, expressing the marker (mean 18.04%±0.99, 
n=37). Among CD45RA+ Tregs, the average expression was significantly lower than 
among the memory Treg subset, but still relatively high (mean 7.25%±1.48, n=37; 
p<0.0001, paired t-test). Responder (CD25-) CD4 T cells, however, had a much lower 
degree of proliferation than regulatory T cells, with Ki67 expression by 2.65% (±0.19) 
and 0.41% (±0.07) of memory and naïve responders, respectively. This confirms our 
earlier observations of a high degree of constitutive proliferation among resting Tregs, 
and extends them to show a high rate of turnover among CD45RA+, naïve, Tregs – 
higher than would be expected from a naïve T cell population.   Chapter 3. Maintenance of human FOXP3+ Tregs throughout life
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Figure 3.3. Proliferation of CD45RO+ and CD45RA+ CD4 T cell subsets
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. Proliferation of CD45RO+ and CD45RA+ CD4 T cell subsets
PBMCs from 37 healthy controls (age range 22-78) were stained ex vivo for CD4, 
and FOXP3 using the FOXP3 staining protocol (see Materials and Methods). Naïve and memory cells 
were differentiated by expression of CD45RO: CD45RO- cells were assumed to be CD45RA+.
Cumulative expression of Ki67 by CD45RA+ and CD45RO+ responders and Tregs. 
strategy for FOXP3+ and FOXP3- subsets. Bottom: Representative staining of Ki67 in subsets of Tregs 
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3.3.2 Proliferation among Treg and responder T cells is consistent 
over time 
In order to be sure that this high rate of proliferation among Tregs was not due to an 
isolated event, but was consistently present, three donors were followed for a period of 
up to 18 weeks. Samples of blood were taken at three different time-points and their 
PBMCs stained for expression of Ki67. Figure 3.4 shows that the proportion of cells 
expressing Ki67 did not change in any subset, demonstrating that a large proportion of 
memory Tregs is dividing at any given time. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. Proliferation of T cell subsets in peripheral blood is consistent over time. 
Peripheral blood was processed on at least three separate occasions each from three healthy donors 
(donor 1: Weeks 0, 2 and 9; donor 2: weeks 0, 3, 5 and 11; donor 3: weeks 0, 15 and 18) and PBMCs 
stained for expression of Ki67, as outlined above. The graphs show expression of Ki67 by each CD4+ T 
cell subset at each time-point. 
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3.2.3 Proliferation within the naïve subset 
CD45RA+ T cells can be divided into CD31+ RTEs and CD31- cells. We therefore 
investigated the rate of proliferation in these two subsets, both among the FOXP3- 
responder pool and FOXP3+ Tregs. Surprisingly, when data from all donors (aged 22-
78) was investigated, a higher proportion of RTE Tregs expressed Ki67 than did their 
CD31- counterparts (see Figure 3.5A), with a mean of 2.87%±0.53 of CD31+ cells 
expressing the marker, compared to 1.54%±0.36 among the CD31- subset (n=18; 
p=0.0427; paired t-test). There was also a greater degree of proliferation among 
CD31+ than CD31- responder naïve cells. When the data from the old (>70) and young 
(<35) donors were analysed separately, it was found that a high proportion of the old 
donors’ RTE Tregs expressed Ki67 (mean 4.08%±0.86), whereas among young donors 
the proportion was lower (mean 1.65%±0.28; p=0.0162; Figure 3.5B). This is likely to 
be the cause of the high RTE Treg turnover observed in the total cohort. On comparing 
the size of the naïve pools with the turnover within each pool, it became apparent that 
there was a greater degree of proliferation by naïve and RTE Tregs in donors with 
smaller pools of these subsets (Figure 3.5C), which is in line with previous 
observations that smaller pools of naïve T cells contain a higher proportion of 
proliferating cells [339], probably as a mechanism to maintain their numbers. 
   Chapter 3. Maintenance of human FOXP3+ Tregs throughout life 
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Figure 3.5. Proliferation of subsets within the CD45RA+ pool in old and young 
PBMCs from 18 donors aged 22-78 were stained ex vivo as described above, with the addition of antibody 
specific for the RTE marker CD31. A. Expression of Ki67 by the CD45RA+CD31+ and CD45RA+CD31- 
subsets of both Tregs and responder (FOXP3-) T cells in all donors (n=23 for RO, 18 for RA subsets). B. 
Ki67 expression in all Treg subsets (CD45RO+, CD45RA+CD31+ and CD45RA+CD31-) in old donors 
(>70 years of age; n=10 for RO, 9 for RA subsets) compared with young donors (<35 years of age; n=13 
for RO, 9 for RA subsets) C. Graph comparing size of CD45RA+ pool within the FOXP3+ population and 
percentage of CD45RA+ expressing Ki67. (n=18) Right: Graph comparing size of RTE pool within the 
FOXP3+ population and percentage of RTE Tregs expressing Ki67. (n=18). 
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3.3.3 Stimulation-induced proliferation of naïve Tregs drives them 
into the memory pool 
CD45RA+ Tregs express a lower degree of Ki67 than CD45RO+ Tregs but are 
nevertheless proliferating. We hypothesised that on proliferation the CD45RA+FOXP3+ 
cells were being driven into the CD45RO+ pool. To investigate the rate at which naïve 
Tregs downregulated CD45RA and upregulated CD45RO, CD45RA+ cells, both Tregs 
and responder T cells, were sorted using a fluorescent cell-sorter and stimulated using 
anti-CD3- and anti-CD28-coated beads and their phenotypes evaluated at intervals. On 
proliferation, CD45RA+ Tregs rapidly downregulated expression of CD45RA and were 
almost universally CD45RO+ by day 4 (Figure 3.6A and B). Cells were confirmed to be 
dividing by the presence of large numbers of blast cells, as seen on forward scatter 
plots obtained via flow cytometry (not shown). This suggests that the lower rate of 
proliferation seen ex vivo among CD45RA+ compared to CD45RO+ Tregs may be 
explained, at least partially, by the fact that on dividing, CD45RA+ Tregs convert to 
show a memory, CD45RO+ phenotype. This observation confirms that CD45RO+ 
Tregs are likely to be generated from the CD45RA+ Treg pool by proliferation. 
   Chapter 3. Maintenance of human FOXP3+ Tregs throughout life
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Figure 3.6. CD45RA+ Tregs acquire expression of CD45RO upon stimulation
CD45RA+ Tregs and responder CD4 T cells were isolated using MACS technology and cultured for up to 7 
days in the presence of anti
intervals throughout the culture period and stained for exp
Representative dotplots showing CD45RA/RO expression by Tregs and responders on days 0, 3 and 4 of 
stimulation, as well as unstimulated cells cultured over the same period. 
CD45RO expression by CD45RA+ Tregs and responder CD4 T cells.
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Maintenance of human FOXP3+ Tregs throughout life 
. CD45RA+ Tregs acquire expression of CD45RO upon stimulation
CD45RA+ Tregs and responder CD4 T cells were isolated using MACS technology and cultured for up to 7 
days in the presence of anti-CD3/anti-CD28 coated beads (0.1 beads/cell). Samples were taken at 
intervals throughout the culture period and stained for expression of CD45RA and CD45RO. 
Representative dotplots showing CD45RA/RO expression by Tregs and responders on days 0, 3 and 4 of 
stimulation, as well as unstimulated cells cultured over the same period. B. Graph showing acquisition of 
by CD45RA+ Tregs and responder CD4 T cells. 
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. CD45RA+ Tregs acquire expression of CD45RO upon stimulation 
CD45RA+ Tregs and responder CD4 T cells were isolated using MACS technology and cultured for up to 7 
CD28 coated beads (0.1 beads/cell). Samples were taken at 
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3.4 Phenotype and function of naïve and memory Tregs  
Some differences in phenotype between naïve and memory Tregs have already been 
elucidated – for example, the former are known to have lower expression of CD25 and 
some chemokine receptors [221]. This study aimed to expand upon the known 
differences between the two subsets, focussing particularly on molecules suspected to 
be involved in Treg function. The ectonucleases CD39 and CD73 have been postulated 
to cooperate to produce suppressive pericellular adenosine [215, 216] and CTLA-4 has 
been suggested to function in a number of ways to mediate suppression [59, 255, 257]. 
 
3.4.1 Differences in surface phenotype between naïve and memory 
Tregs 
CD39 and CD73 have recently been strongly suggested to be involved in the function 
of murine Tregs [215, 216], via breakdown of ATP to adenosine, which then binds 
inhibitory A2A receptors on the target cell. We investigated the expression of these 
proteins on the CD45RA+ and CD45RO+ human Treg subsets, analysing expression 
levels via flow cytometry. We found a surprisingly low degree of expression of CD73 on 
human Tregs (mean 6.23%±0.93), and also very little expression on responder CD4+ T 
cells (mean 13.9%±2.2). Higher proportions of cells within the total lymphocyte gate 
expressed the marker, and with higher levels of expression (Figure 3.7A), indicating 
that the expression of CD73 is greater on lymphocyte types other than T cells (mean 
24.8%±3.2; p=0.0009 compared with CD4+FOXP3+ cells, p=0.0075 compared with 
CD4+FOXP3- cells; n=6). 
 
CD39, however, was expressed by a high proportion of human Tregs, as has been 
previously reported ([215, 216]; Figure 3.7B), with a mean of 60.6%±4.0 expressing the 
marker (n=17). Expression by responder CD4 T cells was highly-significantly lower 
than Tregs’ expression (mean 5.83%±1.2; p<0.0001). On investigating CD39 
expression by CD45RO+ and CD45RA+ subsets within Tregs and responders, we 
found a significantly smaller proportion of naïve than memory cells expressed the 
marker (Figure 3.7C). A mean of 79.5%±1.715 stained positive for CD39, but only a 
small minority of CD45RA+ Tregs did so (mean 12.8%±2.8; p<0.0001; n=8). These 
data may be explained by the fact that CD45RA+ Tregs are less likely to have been 
activated: CD39 is a T cell activation marker [217]. 
   Chapter 3. Maintenance of human FOXP3+ Tregs throughout life
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Figure 3.7. Surface expression of CD39 and CD73 on human CD4 
cells 
PBMCs were stained ex vivo
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Right: Cumulative data. (n=6) 
(n=17) C. CD39 expression by CD45RO+ and CD45RA+ subsets. (n=8)
showing CD39 and CD73 coexpression
CD73
Maintenance of human FOXP3+ Tregs throughout life 
total FOXP3- ROFOXP3+ RAFOXP3+ ROFOXP3-
0
10
20
30
40
50
60
70
80
90 ***
***
**
%
 
C
D
3
9
-
p
o
s
i
t
i
v
e
CD4+FOXP3+ CD4+FOXP3- total lymphocytes
0
10
20
30
40
***
*
**
%
 
C
D
7
3
-
p
o
s
i
t
i
v
e
 
C.  
 
Figure 3.7. Surface expression of CD39 and CD73 on human CD4 Tregs
ex vivo from healthy donors aged between 21 and 86. A. Left
histograms showing CD73 expression by CD4+ T cells (FOXP3+ and FOXP3-) and total lymphocytes. 
Cumulative data. (n=6) B. CD39 expression by CD4+ FOXP3+ cells and CD4+ FOXP3
CD39 expression by CD45RO+ and CD45RA+ subsets. (n=8) D. Representative staining 
showing CD39 and CD73 coexpression on FOXP3+ and FOXP3- CD4+ T cells. 
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Figure 3.9. CTLA-4 expression by human CD4 
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4 expression by human CD4 Tregs and responder T cells.
ex vivo from healthy donors aged 22-50 years. A. Representative staining of CTLA
(intracellular) on FOXP3+ and FOXP3- CD4+ T cell subsets. B.Surface CTLA-4 expression by subsets of 
human CD4 T cells. CTLA-4 was detected by incubation of live cells with anti-CTL
at 37° C in the dark. This was followed by staining for other markers. (n=6) C. Intracellular CTLA
expression by subsets of human CD4 T cells. Anti-CTLA-4 antibody was added along with anti
after cell fixation and permeabilisation, to give intracellular as well as surface staining. (n=7)
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3.4.4 CD39 is not required for suppression by human FOXP3+ Tregs 
CD39 has previously been shown to be necessary for in vitro suppression by murine 
FOXP3+ regulatory T cells [215, 216]. To determine whether it is required for the 
function of their human counterparts, CD39+ cells were depleted from the Treg 
population by MACS (Figure 3.12A). The CD39- Tregs’ capacity to suppress 
proliferation and IFN-γ and IL-2 production was compared to total Tregs. No difference 
was found in the suppressive capacity of total and CD39- Tregs (Figure 3.12B). 
 
CD39 is an activation marker, and cells that were initially CD39- could therefore 
upregulate it upon stimulation. Consequently, cells were stained for CD39 expression 
again at the time the readout of suppression was taken; no upregulation of CD39 was 
observed on the CD39- Tregs by this point, day 2 (Figure 3.12C), suggesting that 
CD39 is not a necessary mediator of human FOXP3+ Treg suppression. 
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Figure 3.12. CD39 expression is not necessary for suppression by human CD25
regulatory T cells. 
CD39-expressing cells were depleted from the Treg population and their suppressive capacity compared 
to that of total Tregs from the same donor. 
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3.5 Induction of FOXP3+ Tregs via anergy 
Earlier data in this study indicate that CD45RA+ Tregs proliferate to a greater degree in 
the old, and hence contribute to maintenance of the Treg pool. However, by the age of 
80 the size of this subset is extremely small, limiting its potential to replenish the whole 
pool of Tregs alone, even with the increased proliferation we observed. It is known that 
Tregs can be induced peripherally via several mechanisms, including TGF-β and 
retinoic acid [78, 211, 232, 235]. However, work by our group has suggested that 
anergised responder CD4+ T cells may also have suppressive capacity [314]. 
 
In order to explore the potential of anergy induction to generate regulatory T cells, we 
anergised PPD-specific CD4 T cells (see Materials and Methods) using various 
concentrations of plate-bound anti-CD3 without any costimulation. Figure 3.13A shows 
the impaired response of these anergised cells to restimulation with PPD. We then 
analysed the PPD-stimulated proliferation of non-anergised PPD-specific CD4+ T cells, 
with and without the addition of anergised cells. As seen in Figure 3.13B, proliferation 
of the unanergised responders was reduced by the anergised cells, particularly those 
anergised with higher concentrations of anti-CD3. Figure 3.14 shows an increase in 
expression of FOXP3 on the protein level in these cells; this acquisition of FOXP3 
expression appears to be associated with acquisition of suppressive capacity, 
suggesting that these are induced regulatory T cells. 
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Figure 3.13. Anergised CD4+ T cells acquire suppressive ability. 
PPD-specific CD4+ T cells were anergised with varying concentrations of anti-CD3 (OKT3), then 
cocultured with APCs and 1µg/ml PPD for 5 days before proliferation was analysed. A. Proliferation 
(measured by incorporation of 
3H-thymidine) of T cells anergised with 0, 0.05, 0.1 and 0.5 µg/ml anti-CD3. 
B. Anergised cells were cultured with non-anergised PPD-specific CD4+ T cells, along with 1µg/ml PPD 
and APCs. Graph shows proliferation of non-anergised PPD specific cells alone (Control), and then 
proliferation on coculture of these cells with T cells anergised with increasing concentrations of anti-CD3. 
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3.6 Discussion 
This chapter concerns the maintenance throughout life of the pool of regulatory cells 
within the CD4+ T cell subset. These cells, known as Tregs, are thought to be 
generated within the thymus; however, in adults, during and after thymic involution, it is 
postulated, although still currently controversial, that peripheral conversion of 
conventional CD4+ T cells may play a role in maintaining the Treg pool [228, 340]. The 
precise contributions of the thymus and periphery in maintaining the Treg population 
throughout life are a still a matter of debate. 
 
In the first part of the chapter we sought to characterise the composition of the Treg 
pool at different stages of adult life. At around age 20, a significant proportion of Tregs 
was found to express CD45RA and can hence be considered to be naïve; however, by 
the age of 80, this has declined to almost zero. Recent thymic emigrants (RTEs), 
CD45RA+ CD31+ cells, are postulated to be truly naïve, whereas cells which express 
CD45RA but not CD31 are thought to have divided [69, 70]. An even smaller proportion 
of the Treg pool was found to have an RTE phenotype and this proportion also 
declined with age. However, the proportion of the CD4+ T cell pool as a whole that has 
a Treg phenotype increases slightly with age, despite maintenance of CD4+ T cell 
numbers in the peripheral blood with age (data not shown) suggesting that 
compensatory mechanisms are keeping the Treg pool replenished despite the 
declining capacity of the thymus. This could be peripheral conversion of conventional 
CD45RO+ CD4+ T cells to CD45RO+ Tregs, or proliferation of thymically-produced 
Tregs with concomitant conversion to express CD45RO. 
 
Previous work using deuterated glucose has demonstrated a high turnover rate among 
CD45RO+ Tregs, with an estimated doubling time of 8 days (compared to 24 days 
among conventional CD4+ T cells) [228]. In order to further elucidate the proliferation 
rate of Tregs, and to investigate proliferation of the naïve subset, samples were stained 
for the nuclear marker of proliferation, Ki67. This was found in a very high proportion of 
CD45RO+ Tregs: a mean of 18% were Ki67-positive. Proliferation was significantly 
lower among CD45RA+ Tregs, although still higher than that observed among naïve 
responders, with 5% actively dividing ex vivo. Naïve Tregs have been shown to have 
long telomeres [221], in contrast to their memory counterparts [228], so this higher rate 
of proliferation in CD45RA+ Tregs than responders, and their consequent upregulation 
of CD45RO as observed after stimulation in vitro, is highly likely to be a contributor to 
the maintenance of a Treg presence in the old, particularly given the higher rate of Chapter 3. Maintenance of human FOXP3+ Tregs throughout life 
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proliferation observed among RTE Tregs in older subjects. The higher levels of Ki67 
seen among RTE Tregs than CD31- Tregs (and among RTE responders compared to 
CD31- naive responders) may also be caused by residual expression of Ki67 after 
thymic proliferation [341]. 
 
A correlation was seen between smaller naïve Treg pool size and increased 
proliferation of the naïve cells within it, which confirms earlier studies [339]. This 
finding, that smaller pools of naïve T cells tend to proliferate more, may also go some 
way towards explaining the high rate of proliferation among CD45RA+ Tregs in 
general, compared to CD45RA+ or CD45RO+ responder T cells. Even in young adults, 
the CD45RA+ Treg pool is extremely small. An interesting avenue of investigation 
might be the proliferation rates among CD45RA+ Tregs in cord blood, where the 
population is much larger. The high rate of proliferation among CD45RO+ Tregs, 
however, cannot be explained by the small size of the population: even in young adults, 
this population is much larger than the CD45RA+ pool and yet displays much higher 
rates of proliferation. It is clear that these cells have a propensity to divide frequently, 
although it must be stressed that our data cannot rule out the existence of long-lived 
and slowly-dividing memory Tregs, which may also help to sustain the Treg population. 
Mathematical models may help to explain the processes taking place. 
 
The proportion of the Treg pool in adults generated directly in the thymus as opposed 
to peripherally by conversion is still a major subject of investigation. In order to better 
describe the naïve and memory Treg subsets in younger adults, we investigated their 
expression of certain Treg markers, as well as their functional capacity. A marked 
difference in the expression by the two subsets of both CD39 and CTLA-4 was 
observed, despite their suppressive equivalence at a 1:1 ratio with their targets. More 
physiological ratios were only investigated in a preliminary fashion (data not shown), 
although these did not show significant differences in suppression. Additionally, the in 
vitro suppression assay was performed in an APC-free system. A more physiological 
set-up may yet identify differences in suppressive capacity and further work is needed 
to investigate the efficiency with which CD45RA+ and CD45RO+ Tregs suppress when 
they are much lower in number than their targets. 
 
 Although CD39 is postulated in this study to be unnecessary for human Treg 
suppression in general, there nevertheless remains the possibility that CD45RA+ and 
CD45RO+ Tregs – especially if the latter are converted from peripheral responder T 
cells – may function via different mechanisms: the importance of CTLA-4 to Treg Chapter 3. Maintenance of human FOXP3+ Tregs throughout life 
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function is strongly supported by numerous studies in both mouse and man. It is 
important, however, to note that CTLA-4 is an activation marker, and may be 
upregulated on CD45RA+ Tregs prior to suppression. Time did not permit the kinetics 
of CTLA-4 upregulation to be investigated in this study, but this experiment may be 
informative to future work. In addition, the study on the importance of CD39 molecule to 
human Treg suppression used CD39- isolated via MACS. These may have been from 
a different source to the CD39+ cells: they may have been largely naïve, and hence 
potentially suppressing via a different mechanism. Knocking down the expression of 
CD39 in cells that previously expressed the marker would be a more reliable method of 
determining the importance of CD39 to the function of all human Tregs: siRNA studies 
would be a good way of doing this, as well as blocking anti-CD39 antibody. 
 
A number of studies have demonstrated that suppressive function and FOXP3 
expression can be induced in conventional T cells as a result of stimulation in the 
presence of TGF-β or retinoic acid or both. This has been demonstrated both in vitro 
and, in mice, in vivo. In this chapter we investigated the induction of anergy as a 
potential conversion mechanism and demonstrated that it can indeed generate 
suppressive capacity as well as protein expression of the Treg marker, FOXP3. A 
further avenue of investigation would be the potential involvement of T:T presentation 
in the induction of regulatory T cells in vivo. T:T presentation occurs as a consequence 
of upregulation of MHC Class II on activated human T cells [203], although this does 
not occur in mice. Expression of MHC Class II enables these T cells to present 
antigenic peptides to other CD4 T cells. This phenomenon has been shown to result in 
anergy induction in the cells receiving the signal [170, 171], although some studies 
have reported successful activation [172] and the mechanism and role of T:T 
presentation are not yet entirely clear. An immune response generates large numbers 
of T cells in close proximity in the affected tissue. It is possible that T:T presentation 
could induce anergy, and therefore T regulatory capacity, in a number of CD4 T cells 
present at the site as a way of dampening the immune response once it has peaked. 
This mechanism also provides a potential source of additional Tregs, which could be 
antigen-specific, generated via anergy induction during the course of normal immune 
responses during life and replenishing the Treg pool. 
 
Overall, it seems that the thymus, although very small in productive size at advanced 
ages, is still able to contribute somewhat to the Treg pool in old age. However, the 
conversion – perhaps by previously-postulated mechanisms or by anergy induction – of 
peripheral memory responder T cells is still likely to be important. This is supported by Chapter 3. Maintenance of human FOXP3+ Tregs throughout life 
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gene expression analyses, which suggest a strong lineage relationship between 
CD45RO+ Tregs and CD45RO+ responder T cells. Conversion of peripheral 
CD4+CD25- T cells to a regulatory phenotype could continuously support Treg 
numbers and potentially provide antigen-specific Tregs in response to encounters with 
harmless antigens. Indeed, the phenotypic differences between CD45RA+ and 
CD45RO+ Tregs appear to be quite striking, despite their functional equivalence at a 
1:1 ratio. Further work is required to fully evaluate the sources and suppressive 
mechanisms of these cells. Chapter 4. Migration of human FOXP3+ Tregs 
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Chapter 4. Migration of human FOXP3+ 
Tregs 
 
4.1 Introduction 
Tregs, like all T cells, circulate in the blood and lymph but must leave these vessels in 
order to exert their effects in the tissues. They must therefore migrate through the 
endothelium lining these vessels. Transendothelial migration is a multistep process 
initiated when surface molecules on the lymphocyte make contact with selectins on the 
surface of the endothelium. This slows the T cell down, a process termed ‘rolling’ [106, 
113]. The endothelium expresses E-selectin and P-selectin in response to inflammatory 
stimuli [109], and these bind glycoproteins on the T cell such as CLA (bound by E-
selectin) [120, 121]. Firm adhesion of the T cell to the endothelial lining is then possible 
provided the T cell expresses the correct receptors for the integrins present on 
endothelium in that particular tissue, since integrin expression is tissue-specific. 
 
After adherence, the T cell can move through the endothelium in a process termed 
diapedesis [107] and can then travel through the tissue along chemokine gradients 
[138]. This complex process means that in order to reach a particular tissue, a T cell 
must express all the correct receptors to attach to the endothelium and for the 
appropriate chemokines. 
 
We first investigated the migration of human Treg subsets by looking at their 
expression of various chemokine and other homing receptors, to establish where they 
were most likely to migrate to; we then studied the ability of Treg and T-responder 
subsets to migrate through dermal endothelium in vitro, and finally we investigated the 
in vivo localisation of these cells in two different tissues: the skin, an accessible organ 
frequently prone to inflammation, and the bone marrow, a primary lymphoid organ. 
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4.2 Chemokine receptor expression 
The chemokine receptor expression of CD45RO+ and CD45RA+ Tregs was 
investigated. As shown in Figure 4.1, we found high levels of CCR7 expression on both 
subsets of Tregs; this chemokine receptor binds CCL19 and CCL21, produced by cells 
in lymphoid organs [139]. T cells expressing high levels of CCR7 therefore have lymph 
node homing characteristics. 
 
CLA and CCR4, in contrast, are skin-homing markers [121, 138, 142]. CLA is a surface 
marker that binds E-selectin and is expressed by over 90% of skin-infiltrating 
lymphocytes [121]. CCR4 binds TARC (also known as CCL17), which is released by 
dermal keratinocytes [142]. As seen in Figures 4.2 and 4.3, both receptors were 
expressed by a large proportion of CD45RO+ Tregs (mean 42.72%±4.7 positive for 
CLA; 74.87%±5.1 positive for CCR4), but showed significantly lower expression on the 
CD45RA+ subset (p<0.0001 for CLA, p=0.0003 for CCR4). However, expression of 
CLA by CD45RA+ Tregs was significantly higher than that by CD45RA+ conventional T 
cells, and expression of CCR4 tended to be higher on the regulatory cells (CLA mean 
16.4%±4.7 for CD45RA+FOXP3+ cells, mean 2.029%±0.6 for CD45RA+FOXP3- cells, 
p=0.0061; CCR4 mean 20.97%±8.3 CD45RA+FOXP3+ cells positive, mean 3.53%±1.4 
CD45RA+FOXP3- cells positive; p=0.068). This suggests that CD45RO+ Tregs are 
more likely to home to the skin than CD45RA+ Tregs. 
 
We also investigated expression of the bone marrow homing chemokine receptor, 
CXCR4. This protein binds to the chemokine CXCL12 or SDF-1, produced in large 
quantities in the bone marrow [141, 342]. We found higher expression of CXCR4 on 
both CD45RA+ Tregs and CD45RA+ responders compared to CD45RO+ cells (Figure 
4.4), suggesting that naïve T cells have a strong propensity to home to the bone 
marrow. (MFI of CXCR4 on CD45RA+FOXP3+: 53.96±12.4; CD45RO+FOXP3+: 
15.99±2.6; p=0.009. MFI of CXCR4 on CD45RA+FOXP3-: 26.66±3.0; 
CD45RO+FOXP3-: 14.45±2.3; p=0.0005.) CXCR4 expression on CD45RA+FOXP3+ 
cells was also significantly higher than on CD45RA+FOXP3- cells (p=0.05). 
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Figure 4.1. CCR7 expression by subsets of responder and regulatory T cells
A. Mean fluorescence intensity of CCR7 expression on CD45RA+ and CD45RO+ responder (FOXP3
and regulatory (FOXP3+) CD4+ T cells (n=7). 
subsets of FOXP3+ and FOXP3
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expression by subsets of responder and regulatory T cells. 
Mean fluorescence intensity of CCR7 expression on CD45RA+ and CD45RO+ responder (FOXP3-) 
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Figure 4.2. CLA expression by subsets of responder and regulatory T cells.
A. Mean fluorescence intensity of CLA expression on CD45RA+ and CD45RO+ responder (FOXP3
regulatory (FOXP3+) CD4+ T cells (n=7). 
of FOXP3+ and FOXP3- CD4+ cells.
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Figure 4.2. CLA expression by subsets of responder and regulatory T cells. 
Mean fluorescence intensity of CLA expression on CD45RA+ and CD45RO+ responder (FOXP3-) and 
by naive and memory subsets Chapter 4. Migration of human FOXP3+ Tregs
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Figure 4.3. CCR4 expression by subsets of responder and regulatory T cells.
A. Mean fluorescence intensity of CCR4 expression on CD45RA+ and CD45RO+ responder (FOXP3
and regulatory (FOXP3+) CD4+ T cells (n=7). 
subsets of FOXP3+ and FOXP3
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Figure 4.3. CCR4 expression by subsets of responder and regulatory T cells.
Mean fluorescence intensity of CCR4 expression on CD45RA+ and CD45RO+ responder (FOXP3
and regulatory (FOXP3+) CD4+ T cells (n=7). B. Representative staining of CCR4
FOXP3- CD4+ cells. 
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Figure 4.3. CCR4 expression by subsets of responder and regulatory T cells.  
Mean fluorescence intensity of CCR4 expression on CD45RA+ and CD45RO+ responder (FOXP3-) 
CCR4 by naive and memory Chapter 4. Migration of human FOXP3+ Tregs
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Figure 4.4. CXCR4 expression by subsets of responder and regulatory T cells. 
A. Mean fluorescence intensity of CXCR4 expression on CD45RA+ and CD45RO+ responder (FOXP3
and regulatory (FOXP3+) CD4+ T cells (n=7). 
subsets of FOXP3+ and FOXP3
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Figure 4.4. CXCR4 expression by subsets of responder and regulatory T cells. 
Mean fluorescence intensity of CXCR4 expression on CD45RA+ and CD45RO+ responder (FOXP3
and regulatory (FOXP3+) CD4+ T cells (n=7). B. Representative staining of CXCR4
FOXP3- CD4+ cells. 
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Figure 4.4. CXCR4 expression by subsets of responder and regulatory T cells.  
Mean fluorescence intensity of CXCR4 expression on CD45RA+ and CD45RO+ responder (FOXP3-) 
CXCR4 by naive and memory Chapter 4. Migration of human FOXP3+ Tregs 
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4.3 Transendothelial migration of Tregs in vitro 
A greater proportion of CD4+ Tregs than responders expresses the skin-homing 
markers CLA and CCR4, implying that regulatory T cells should have a greater 
capacity than responders to migrate into the skin across dermal endothelium. To test 
this hypothesis, we followed their migration using an in vitro system using primary 
endothelial cells. We first compared the migration of CD45RO+ responder CD4+ T 
cells and CD45RO+ Tregs over monolayers of stimulated and unstimulated 
endothelium. We then extended our investigations to include the CD45RA+ subsets of 
both responder T cells and Tregs. 
 
The cells were added to a stimulated (with IFN-γ and TNF) or unstimulated dermal 
endothelial monolayer and the extent of migration after 2 hours and 4 hours was 
estimated using time-lapse microscopy. Figure 4.5 shows a number of still images from 
time-lapse videos illustrating the extent of migration seen by Tregs or responders on 
stimulated and unstimulated endothelium (also see Movies 1-4 on the attached CD or 
at www.mediafire.com/migrationvideos). Migrated cells appear darker, wider and flatter 
than cells that are still on the upper surface of the endothelium, with no ‘halo’. Overall, 
no difference was seen in the migratory capacity of CD45RO+ Tregs and responder T 
cells to cross either stimulated or unstimulated dermal endothelium (Figure 4.6A), after 
2 hours (mean percentage migrated over stimulated endothelium: CD45RO+FOXP3-: 
22.63%±6.3; CD45RO+FOXP3+: 28.57%±5.4; p=0.6304; over unstimulated 
endothelium: CD45RO+FOXP3-: 4.833%±2.1; CD45RO+FOXP3+: 2.067%±0.72; 
p=0.3408) or 4 hours (mean percentage migrated over stimulated endothelium: 
CD45RO+FOXP3-: 20.46%±4.7; CD45RO+FOXP3+: 13.74%±3.5; p=0.2760; over 
unstimulated endothelium: CD45RO+FOXP3-: 1.70%±1.7; CD45RO+FOXP3+: 
4.0%±0.51; p=0.3848). 
 
On investigation of the transendothelial migratory capacity of CD45RA+ and CD45RO+ 
cells among responders and regulatory T cells, we found that naïve responders and 
regulatory T cells tended to migrate less efficiently than their CD45RO+ counterparts 
(Figure 4.6B and see Movies 5 and 6 on the attached CD), although due to a large 
degree of inter-patient variation, this trend was not significant (mean percentage 
migrated: CD45RO+FOXP3+ 14.13%±5.0; CD45RA+FOXP3+ 3.68%±2.6; p=0.08). 
CD45RA+ Tregs also migrated more efficiently than their CD45RA+ responder 
counterparts (mean percentage migrated: CD45RO+FOXP3- 15.85%±2.2; 
CD45RA+FOXP3- 0.638%±0.36; p=0.007).   Chapter 4. Migration of human FOXP3+ Tregs
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Figure 4.5. Transendothelial migration of human primary T cells.
Stills from time-lapse videos illustrating the appearance of migrated (indicated by white arrows) 
unmigrated (indicated by red arrows) cells. Cells were loaded onto a primary endothelial 
and imaged after 2 hours. 
CD45RO+CD4+ CD25
hi Tregs on stimulated endothelium. 
endothelium. 
Migration of human FOXP3+ Tregs 
. Transendothelial migration of human primary T cells. 
lapse videos illustrating the appearance of migrated (indicated by white arrows) 
nmigrated (indicated by red arrows) cells. Cells were loaded onto a primary endothelial 
and imaged after 2 hours. A. CD45RO+ CD4+ CD25- responders on stimulated endothelium. 
Tregs on stimulated endothelium. C. Responder CD4+ T cells on unstimulated 
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lapse videos illustrating the appearance of migrated (indicated by white arrows) and 
nmigrated (indicated by red arrows) cells. Cells were loaded onto a primary endothelial cell monolayer 
responders on stimulated endothelium. B. 
T cells on unstimulated Chapter 4. Migration of human FOXP3+ Tregs 
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Figure 4.6. Comparison of transendothelial migration by subsets of responder and 
regulatory T cells. 
A. Migration of responder (CD25-) and regulatory (CD25
hi) CD4 T cells over stimulated and unstimulated 
primary endothelium at early (2 hours) and late (4 hours) timepoints. CD45RO+ cells were isolated to 
ensure a fair comparison. (n=3) B. Transendothelial migration by naïve and memory subsets of responder 
and regulatory CD4 T cells, over stimulated endothelium, after 4 hours. (n=4) C. Paired comparisons of 
migration by Treg (left) and responder (right) CD45RA+ and CD45RO+ subsets. (n=4) Chapter 4. Migration of human FOXP3+ Tregs 
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4.4 Tregs in normal skin 
Having established that CD45RO+ Tregs have a capacity to migrate through stimulated 
but not unstimulated dermal endothelium, we investigated tissue sections from normal, 
uninflamed skin to establish the extent of dermal infiltration by different subsets of 
Tregs in vivo under non-inflammatory conditions. Although low numbers of CD4+ T 
cells were found in unstimulated skin, a high proportion of these cells expressed 
FOXP3 (not shown). 
 
We investigated normal skin sections using immunofluorescence microscopy to 
determine the proportions of FOXP3+ cells in normal skin expressing CD45RA and 
CD45RO; representative staining is seen in Figure 4.7A and B. In all infiltrates counted 
in sections from five different donors, only two FOXP3+ cells expressing CD45RA were 
detected. Table 6.1 shows the absolute counts obtained in sections from donors; young 
donors were used to look for CD45RA+FOXP3+ cells, but unfortunately had few 
FOXP3+ cells in many of the sections examined. There is however a clear increase in 
the propensity of skin FOXP3+ cells to be CD45RO+ compared to CD45RA+. This 
supports our previous data on the relative migration of CD45RA+ compared to 
CD45RO+ Tregs across endothelium in vitro. 
 
 
   Chapter 4. Migration of human FOXP3+ Tregs 
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Figure 4.7. FOXP3+ cells are predominantly CD45RO+. 
Punch biopsies were taken from healthy donors at sites of unchallenged skin, and sections stained for 
expression of FOXP3, CD45RA and CD45RO. A. Representative photograph showing expression of 
CD45RO (green) and FOXP3 (red) in unchallenged skin. B. Representative photograph showing 
expression of CD45RA (green) and FOXP3 (red) in unchallenged skin. 
   Chapter 4. Migration of human FOXP3+ Tregs
 
 
Table 6.1. Counts of CD45RA+ and CD45RO+ FOXP3+ cells in unchallenged skin
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4.5 CD45RA+ Tregs preferentially home to the bone 
marrow 
CD45RA+, naïve, T cells are known to home preferentially to secondary lymphoid 
organs via high expression levels of CCR7 [106, 138]. High expression of the bone-
marrow-homing chemokine receptor, CXCR4, was observed on CD45RA+ responder 
and especially regulatory CD4 T cells. The study was extended to investigate whether 
there was any evidence of preferential homing to the bone marrow by these cells. 
 
4.5.1 CD45RA+ cells form a higher proportion of the FOXP3+ pool in 
the bone marrow than in the peripheral blood 
Bone marrow, obtained from healthy bone marrow donors, was stained for expression 
of CD4, FOXP3 and CD45RA, at the same time as peripheral blood from the same 
donors. As shown in Figure 4.8, an enrichment of CD45RA+ cells was found among 
CD4+FOXP3+ cells, compared to the proportion observed among peripheral blood 
Tregs from the same donor. A corresponding reduction in the proportion of CD45RO+ 
Tregs was seen. No significant change in the proportion of CD45RA+ or CD45RO+ 
FOXP3- cells was seen compared to peripheral blood, however (not shown), indicating 
that this is a Treg-specific phenomenon. 
 
4.5.2 CD45RA+FOXP3+ cells are proliferating at the same rate in 
bone marrow as in the peripheral blood 
We hypothesised that the increased proportion of CD45RA+ cells among the bone 
marrow Treg population could be generated by increased proliferation among these 
cells, with the cytokine milieu of the bone marrow preventing loss of CD45RA 
expression. To establish whether this was the case, bone marrow and their paired 
peripheral blood samples were stained for expression of the nuclear marker of 
proliferation, Ki67. Figure 4.8 shows that the degree of proliferation among 
CD45RA+FOXP3+ cells from bone marrow compared to peripheral blood was not 
significantly different (bone marrow median: 5.36%; peripheral blood median: 5.24%; 
p=1.0; n=6). Proliferation among both CD45RO+ and CD45RA+ CD4+ responder 
subsets was also the same as that in peripheral blood. However, there was reduced 
proliferation of CD45RO+ FOXP3+ Tregs in the bone marrow compared to the 
peripheral blood (bone marrow median: 8.29%; peripheral blood median: 11.48%; 
p=0.002; n=6), which could lead to a relative decrease in the proportion of CD45RO+ 
cells in the bone marrow Treg pool.   Chapter 4. Migration of human FOXP3+ Tregs
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Figure 4.8. CD45RA+ Tregs preferentially home to the bone marrow.
Bone marrow and PBMC samples from the same healthy donors were investigated for the prevalence of 
Treg subsets and proliferation. 
(left) and CD45RO (right) in bone marrow and peripheral blood. 
Treg and responder CD45RA+ and CD45RO+ subsets in peripheral blood and bone marrow. 
Representative dotplots showing Ki67 expression by CD45RA+ and CD45RO+ Treg and responder 
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4.6 Discussion 
Previous studies on human Tregs have focused on cells isolated directly ex vivo from 
peripheral blood, or induced in vitro, but much less is known about the presence and 
behaviour of these cells in the tissues. In this study we set out to investigate the 
migratory behaviour of these cells within the healthy individual. We found that 
CD45RO+ Tregs were more likely than the CD45RA+FOXP3+ subset to home to the 
skin, with a very large proportion expressing CLA and CCR4. Intriguingly, however, 
CD45RA+ Tregs do express higher levels of both markers than CD45RA+ responders. 
This led us to investigate whether CD45RA+ FOXP3+ cells were present in healthy, 
uninflamed skin. 
 
The migration of CD45RO+ Tregs and CD45RO+ responders through a monolayer of 
dermal endothelium was observed in vitro. We isolated CD45RO+ cells from both 
subsets for a fair comparison. We found that Tregs and responders had an equal 
migratory capacity, despite the fact that a larger proportion of CD45RO+ Tregs than 
CD45RO+ responders expresses CLA. The proportion migrated did not appear to 
increase between 2 hours’ and 5 hours’ incubation, suggesting that T cells of both 
kinds migrate rapidly if they express the right receptors, and neither cell type showed 
much capacity to migrate across unstimulated endothelium. This latter point is 
intriguing given the small but significant presence of both conventional CD4+ T cells 
and CD4+ FOXP3+ T cells in healthy, unchallenged skin [314]. These may be cells 
remaining after a previous challenge, or perhaps representative of the very small 
proportion of cells that will migrate through unstimulated endothelium. 
 
We extended our investigations of migration to include the CD45RA+ subsets of the 
Treg and responder pools and found little migration by either CD45RA+ Tregs or 
responder cells. Although CD45RA+ responder T cells migrated significantly less well 
than CD45RO+ responders, the difference in migration between the Treg subsets was 
not significant, despite strong trends. This may be due to donor variation. It is, 
however, possible to conclude that CD45RO+ Tregs are more likely to migrate through 
endothelium than CD45RA+ Tregs, and that therefore upon investigation of sections 
from human skin, all FOXP3+ cells would be expected to express CD45RO and not 
CD45RA. 
 
The evidence from skin biopsies supported this. In sections of normal, unstimulated 
skin from 5 old and young donors, only two FOXP3+ cells expressed CD45RA. In Chapter 4. Migration of human FOXP3+ Tregs 
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contrast, when stained for CD45RO, expression of this marker by FOXP3+ cells was 
almost universal. It seems clear that CD45RA+ Tregs do not preferentially home to 
skin, whereas skin-homing by CD45RO+ Tregs is a previously-observed phenomenon 
[315]. 
 
We found that bone marrow Tregs had a higher proportion of CD45RA+ cells within the 
pool compared to Tregs from peripheral blood. CD45RO+ cells were correspondingly 
decreased in the bone marrow. In contrast, there was no alteration in the proportions of 
CD45RA+ and CD45RO+ cells among responders, despite higher expression of 
CXCR4 cells by the naïve cells in this pool; this suggests that mechanisms other than 
the CXCL12-CXCR4 interaction may be causing the enrichment of CD45RA+ Tregs in 
the bone marrow. We investigated expression of Ki67 by all the subsets in an attempt 
to ascertain whether the CD45RA+ cells were simply proliferating more in the bone 
marrow environment, but could find no difference in the extent of proliferation in this 
subset. 
 
There was a lower degree of Ki67 expression amongst CD45RO+ Tregs in the bone 
marrow, although no significant differences in the proliferation rates of the other Treg 
and responder T cell subsets. This lower proliferation rate amongst CD45RO+ meant 
that in bone marrow, there is no significant difference in the rate at which the two Treg 
subsets are cycling. This is in contrast to the blood, where CD45RO+ cells are 
significantly more proliferative; this observation is a reminder that the blood, while a 
useful and highly-accessible source of ex vivo cells, does not necessarily provide a 
representative picture of the behaviour of immune cells elsewhere in the body. The 
altered cycling rate amongst CD45RO+ regulatory T cells may contribute to the altered 
proportions of the subsets, but given their high expression of CXCR4, it seems 
probable that CD45RA+ Tregs are actively homing to the site. The reason for this 
preference is not yet clear, but it is possible that the cytokine environment of the bone 
marrow is conducive to the survival or development of CD45RA+ Tregs. They may also 
be able to proliferate in this environment without losing CD45RA expression. The bone 
marrow has also been demonstrated to be a secondary, as well as a primary, lymphoid 
organ [Feuerer et al, 2003]. It is possible that these cells are primed here. 
 
These results show a distinct migration pattern for CD45RA+ and CD45RO+ Tregs. 
CD45RO+ Tregs seem likely to home to the skin. CD45RA+ Tregs, on the other hand, 
show a preference for the bone marrow and seem less likely to be found at sites prone 
to inflammation. Further investigation is required to establish the reason for this Chapter 4. Migration of human FOXP3+ Tregs 
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differential migration, and whether these cells home to different environments for 
survival purposes or in order to fulfil different roles. Additionally, although Tregs and 
responders showed an equal capacity for rapid transendothelial migration when 
isolated, an area that remains to be investigated is the interaction between the two cell 
types on an endothelial monolayer. It is possible that, when allowed to interact, Tregs 
may affect the migration of responders; Tregs have previously been reported to 
interfere with the rolling and adhesion of CD4+CD25- cells in vivo [248]. Chapter 5. Human FOXP3+ Tregs in the immune response in vivo 
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Chapter 5. Human FOXP3+ Tregs in the 
immune response in vivo 
 
5.1 Introduction 
The previous two chapters investigated the phenotype and behaviour of regulatory T 
cells, and their CD45RO+ and CD45RA+ subsets, both in the blood and in two distinct 
tissues, the skin and bone marrow, in the normal, healthy individual. However, Tregs 
exist to exert a suppressive function, not only reducing the ever-present risk of 
autoimmunity in the periphery but also dampening immune responses once they are no 
longer required, in order to prevent chronic inflammation and immunopathology. To 
investigate whether responder T cells can convert to regulatory T cells during an 
immune response, we initially investigated the upregulation of FOXP3 in response to 
stimulation of CD4+CD25- cells in vitro. A large proportion of these responder T cells 
acquires expression of FOXP3 following stimulation. We showed, however, that this 
expression is purely transient, appears to be linked to proliferation, and that the 
cytokine profile of these activated cells does not match that of FOXP3+ Tregs, which 
means that study of FOXP3+ cells in vivo, especially in an inflammatory environment, 
must be undertaken with caution. 
 
Tregs do, however, participate in immune responses in vivo and these primarily occur 
in the tissues. This chapter seeks to characterise the behaviour and migration of Tregs 
in the skin during the human immune response to a secondary antigen challenge, 
namely PPD (to which most adults have pre-existing immunity, having been vaccinated 
with the BCG vaccine) in vivo. Following secondary antigen challenge in the skin, there 
is an influx of lymphocytes, many of which are CD4+ and a constant proportion of 
which expresses FOXP3 [314]. Since FOXP3 expression can be acquired transiently 
by non-Tregs in vitro, we sought to establish whether these FOXP3+ cells were true 
Tregs via detailed investigation of their phenotype and cytokine production.  
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5.2 Acquisition of FOXP3+ expression after stimulation 
of non-Treg CD4+ T cells in vitro 
Previous studies have indicated that stimulation of human CD4+CD25- T cells results 
not just in acquisition of expression of CD25, but also the induction of FOXP3 
expression in these conventional T cells. This expression is not accompanied by 
suppressive function [196]. In order to further investigate the kinetics of this 
phenomenon, CD4+CD25- cells were isolated from peripheral blood and stained with 
CFSE. They were then incubated with anti-CD3, anti-CD28 coated beads as a stimulus 
for up to seven days. Samples were taken at day 1, day 3, day 5 and day 7 and 
investigated for expression of FOXP3 and CD25. We also stained for Ki67, to measure 
proliferation, and CFSE, to provide a proliferative history of the cells: those which have 
divided more have a weaker CFSE signal. As shown in Figure 5.1, FOXP3 expression 
preceded Ki67 expression. After 24 hours, around 10% of cells showed expression of 
FOXP3, but these cells did not express Ki67. FOXP3 expression peaked at day 3, by 
which time almost all FOXP3+ cells were Ki67+ and most showed evidence of division, 
both by expression of Ki67 and dilution of CFSE. FOXP3 expression then fell, until by 
day 7 only around 7% of the cells expressed the marker; the vast majority were, 
however, still dividing. 
 
Subsequent investigation of the cytokine profiles of stimulated responder cells revealed 
similar proportions of both FOXP3- and FOXP3+ cells producing the pro-inflammatory 
cytokines IL-2 and IFN-γ (Figure 5.2). This supports the suggestion that those 
stimulated responder CD4 T cells which have upregulated FOXP3 expression have not 
acquired a regulatory phenotype. The transient but widespread observed expression of 
FOXP3 makes analysing activated cells difficult. Steps must be taken to ensure that 
FOXP3+ T cells in an inflammatory environment are true Tregs. 
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Figure 5.1. Acquisition of 
CD4+CD25- cells were isolated from peripheral blood and stained with 0.5µM CFSE. They were incubated 
with anti-CD3, anti-CD28-
7 and stained for expression of CD25, FOXP
occurred. 
Human FOXP3+ Tregs in the immune response in vivo 
. Acquisition of FOXP3 expression by stimulated cells. 
isolated from peripheral blood and stained with 0.5µM CFSE. They were incubated 
-coated beads for seven days, with samples taken at day 1, day3, day 5 and day 
ned for expression of CD25, FOXP3 and Ki67. Dilution of CFSE indicates cell divisions have 
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isolated from peripheral blood and stained with 0.5µM CFSE. They were incubated 
coated beads for seven days, with samples taken at day 1, day3, day 5 and day 
ndicates cell divisions have Chapter 5. Human FOXP3+ Tregs in the immune response 
 
 
 
 
 
 
 
 
 
Figure 5.2. Cytokine production by FOXP3
CD25- responder T cells were isolated and stimulated 
After 3 days the cells were fixed and 
show IFN-γ and IL- production 2 by the resultant FOXP3+ (top) and FOXP3
Human FOXP3+ Tregs in the immune response in vivo 
. Cytokine production by FOXP3-expressing stimulated responder CD4 T cells.
responder T cells were isolated and stimulated in vitro with anti-CD3- and anti
After 3 days the cells were fixed and stained for production of pro-inflammatory cytokines. 
production 2 by the resultant FOXP3+ (top) and FOXP3- (bottom) cells.
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expressing stimulated responder CD4 T cells. 
and anti-CD28 coated beads. 
flammatory cytokines. Histograms 
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5.3 Accumulation of FOXP3-expressing cells in human 
skin following secondary antigen challenge 
In order to investigate the kinetics of FOXP3+ T cell accumulation during a secondary 
immune response, skin punch biopsies were taken at days 0, 3, 7 and 14 following 
subcutaneous injection of the PPD antigen, a component of the BCG vaccine. As 
shown in Figure 5.3D, the proportion of CD4+ T cells expressing FOXP3 remained the 
same throughout the immune response. Expression of Ki67 by FOXP3+ cells remained 
relatively constant throughout the course of the immune response (Figure 5.4), at 
around 8-9% (mean day 3: 9.7%±1.1; day 7: 8.1%±2.5; day 14: 7.9%±1.8). 
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Figure 5.3. FOXP3+ cells accumulate at the site of antigen (PPD) challenge. 
Healthy volunteers were subcutaneously injected with PPD antigen and punch biopsies taken at the 
injected site at various different timepoints. Sections from these biopsies were stained for CD4 and 
FOXP3. Representative pictures are shown from A. day 0, B. day 3 and C. day 7 sections, showing CD4 
(green) and FOXP3 (red) expression in unchallenged and inflamed skin. D. Graph showing the proportion 
of CD4+ cells expressing FOXP3 during the course of the immune response.
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Figure 5.4. FOXP3+ cells proliferate in the skin following subcutaneous secondary 
antigen challenge. 
Healthy volunteers were subcutaneously injected with PPD antigen and punch biopsies taken, before 
sections were stained for expression of FOXP3 and Ki67. Representative pictures are shown from A. day 
0, B. day 3 and C. day 7 showing expression of Ki67 (green) and FOXP3 (red) following antigen challenge. 
D. Graph showing expression of Ki67 by FOXP3+ cells (FOXP3+ and Ki67+ cells are yellow) at day 0, day 
3, day 7 and day 14 after antigen challenge.   Chapter 5. Human FOXP3+ Tregs in the immune response in vivo 
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5.4 Phenotypic analysis of FOXP3+ cells accumulating 
in the skin after a secondary antigen challenge 
There is a clear increase in the absolute number of CD4+FOXP3+ T cells present at 
the site of an immune response as the response grows in magnitude, up to a peak at 
day 7, as well as an increase in their proliferation. However, the proportion of CD4+ T 
cells at the site expressing FOXP3 does not increase: the number of FOXP3+ T cells 
becomes larger in line with the total number of CD4+ T cells. It is not clear whether 
these FOXP3-expressing cells really are Tregs or simply activated CD4 T cells. This 
study sought to establish this, by investigating the expression of known Treg markers 
and examining the behaviour of the FOXP3+ and FOXP3- cells at the site. This was 
achieved with the suction blister technique [313, 314], whereby a blister is formed over 
the site of antigen challenge and cells and fluid allowed to accumulate within it for 18 
hours. Cells from the immune reaction move into the blister fluid during this time. The 
fluid is then extracted from the blister and the cells within it purified. They can then be 
analysed by flow cytometry. 
 
5.4.1 CD4+FOXP3+ cells following PPD challenge have a Treg 
phenotype 
We induced suction blisters over the site of PPD challenge, 7 days after subcutaneous 
antigen injection, and stained for FOXP3 and CD4 as well as CD25, CD127 (the IL-7 
receptor α-chain), CD39 and CD27 – all markers of which Tregs are thought to have a 
specific expression pattern. Figure 5.5 shows representative staining of the blister 
FOXP3+ cells for these markers; they are CD25
hi, almost entirely CD27+, largely 
CD39+ and also CD127
lo, which are all recognised characteristics of human Tregs. In 
comparison, staining of FOXP3- cells, also shown in Figure 5.5, revealed some 
expression of CD25 but lower CD27 and CD39 expression, as well as high expression 
of CD127. This is a typical profile of an activated T cell. 
 
In addition to the Treg markers mentioned above, expression of Ki67 by the CD4+ 
blister cells was also investigated. Ki67 expression by FOXP3+ cells in blisters was not 
significantly different from that in the peripheral blood (Figure 5.6), but Ki67 was 
expressed by a mean of 28.8%±10.1 of FOXP3- cells at the site of the immune 
response compared with a mean of 1.7%±0.26 in the peripheral blood – a significant 
increase.  
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Figure 5.5. FOXP3+ cells at the site of an immune response in vivo have regulatory T cell
like phenotypes. 
Suction blisters were formed over the site of a day 7 cutaneous response to PPD and the cells were 
harvested and stained with monoclonal antibodies against the Treg markers 
and CD39. Data are representative of 
 
Human FOXP3+ Tregs in the immune response in vivo 
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Suction blisters were formed over the site of a day 7 cutaneous response to PPD and the cells were 
harvested and stained with monoclonal antibodies against the Treg markers FOXP
are representative of six independent experiments. 
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Figure 5.6. FOXP3+ and F
response are proliferating.
Cells were isolated from a suction blister formed over a day 7 secondary cutaneous response to PPD. 
They were stained for expression of CD4 and 
skin-homing marker, CLA. Data are representative of si
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3+ and FOXP3- CD4+ cells at the site of an ongoing secondary immune 
response are proliferating. 
Cells were isolated from a suction blister formed over a day 7 secondary cutaneous response to PPD. 
They were stained for expression of CD4 and FOXP3, and the proliferation marker, Ki67, as well as the 
homing marker, CLA. Data are representative of six independent experiments.
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CD4+ cells at the site of an ongoing secondary immune 
Cells were isolated from a suction blister formed over a day 7 secondary cutaneous response to PPD. 
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5.4.2 Accumulated CD4+FOXP3+ T cells do not produce pro-
inflammatory cytokines in response to a PPD stimulus 
Although the FOXP3+ cells accumulated at the site of antigen challenge strongly 
resemble Tregs phenotypically, it was still possible that they could be merely activated 
responder (FOXP3-) cells. The ideal test of whether these cells were Tregs would be to 
test their suppressive capacity, but due to the small numbers of cells involved, this 
proved impossible. (Commonly as few as 100,000 cells can be retrieved from a skin 
blister, of which 40,000 express CD4 and a far smaller proportion express FOXP3.) 
Instead, we harvested the total cells from the blister and restimulated them with PPD 
before staining them to detect cytokine production: Tregs should not produce any IL-2 
or IFN-γ in response to stimulation. We found no cytokine production by FOXP3+ cells 
isolated from the blister, in comparison to high levels of IFN-γ and IL-2 produced by the 
FOXP3- CD4+ population (Figure 5.7). The putative Tregs also produced little or no IL-
17 and IL-10. 
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Figure 5.7. FOXP3+ cells at the site of an ongoing cutaneous immune response do not 
produce cytokines. 
Cells were extracted from suction blisters raised over a cutaneous 
stimulated with PMA and ionomycin, then exocytosis was blocked using brefeldin A. Cells were stained for 
expression of CD4, FOXP
experiments. Left. Production of 
Production of IL-2 by FOXP
Human FOXP3+ Tregs in the immune response in vivo 
3+ cells at the site of an ongoing cutaneous immune response do not 
Cells were extracted from suction blisters raised over a cutaneous response to PPD antigen. They were 
stimulated with PMA and ionomycin, then exocytosis was blocked using brefeldin A. Cells were stained for 
OXP3 and the cytokines IFNγ and IL-2. Data is representative of three independent 
Production of IFN-γ by FOXP3+ and FOXP3- blister cells within the CD4+ gate. 
OXP3+ and FOXP3-blister cells within the CD4+ gate. 
118 
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response to PPD antigen. They were 
stimulated with PMA and ionomycin, then exocytosis was blocked using brefeldin A. Cells were stained for 
2. Data is representative of three independent 
blister cells within the CD4+ gate. Right. 
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5.5 Discussion 
Work in this chapter investigates the response of Tregs in an inflammatory 
environment. In vitro, it is clear from work in this chapter and also from previous studies 
[193-196] that stimulated effector CD4 T cells express FOXP3 to relatively high levels, 
and this expression seems to be linked to proliferation since – apart from on day 1 – all 
FOXP3+ cells are also Ki67+. The appearance of FOXP3 before the first expression of 
Ki67 is a curious phenomenon given the fact that Tregs are also generally accepted to 
be anergic in vitro [182, 183, 187], and the ectopic expression of FOXP3 also causes 
anergy in the transformed cells [157-159, 197]. It would seem that the upregulation of 
FOXP3 in response to stimulation does not, however, prevent proliferation or cytokine 
production. FOXP3 expression in an inflammatory environment in vitro cannot be taken 
as a marker for Tregs. 
 
In vivo, however, the situation may be different: FOXP3+ cells appear to be both 
proliferative and true Tregs. We investigated the response of CD4+ T cells to a 
secondary cutaneous challenge, subcutaneous injection of PPD, initially by 
immunofluorescent staining of skin sections. We observed the number of 
CD4+FOXP3+ cells increasing along with the number of CD4+FOXP3- T cells. The 
proportion of FOXP3+ cells stayed the same throughout the course of the response, as 
did their degree of proliferation. 
 
In order to investigate whether these FOXP3+ cells were really Tregs or activated 
immune cells, we formed suction blisters over the area of immune response; the 
immune cells moved into the blister fluid, which was then extracted so that the cells 
could be analysed by flow cytometry. We stained the cells extracted for several 
different Treg markers, including FOXP3 and CD127 (IL-7Rα), as well as a marker of 
proliferation (Ki67) and a marker of differentiation (CD27). We found that the FOXP3+ 
and FOXP3- cells from the blister had very different phenotypes; the FOXP3+ cells 
expressed high levels of the Treg-associated markers CD25 and CD39 and low levels 
of CD127, a classic Treg phenotype [181, 183, 212, 213, 216], whereas the FOXP3- 
cells had the opposite phenotype. Both FOXP3+ and FOXP3- cells largely expressed 
CD27, although the FOXP3+ cells expressed more. Tregs are known to be almost 
universally CD27+ [343]. Curiously, Ki67 was expressed by the FOXP3+ cells to 
approximately the same degree as those isolated from the peripheral blood, but 
FOXP3- cells were proliferating much more than Tregs at the site of the immune 
response. Chapter 5. Human FOXP3+ Tregs in the immune response in vivo 
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The phenotypes described above suggest strongly that the FOXP3+ cells found at the 
site of an in vivo immune response are regulatory T cells. However, the fact that the 
FOXP3+ cells isolated from blisters do not produce pro-inflammatory cytokines is 
stronger evidence. FOXP3+ cells isolated from an in vivo immune response do not 
produce notable levels of either IFN-γ or IL-2; if they were simply activated cells they 
would be expected to produce very high levels of one or both of these cytokines, as the 
FOXP3- cells from the blister do. The strongest possible evidence would come from 
isolating these cells and demonstrating that they suppress. However, often only 
100,000 cells can be harvested from a blister. Of these, around 40-60% are CD4+ and 
around 10-20% of the CD4+ cells express FOXP3. This number of cells is too low to 
pass through magnetic columns and obtain a usable yield of Tregs; we attempted to 
pan the cells, using 96-well plates coated with anti-CD25 and anti-CD39 antibody, but 
could not achieve the required purities for a suppression assay of any kind via this 
method. The number of cells was so low that sorting them would have resulted in many 
dying, if indeed pure populations could be obtained by sorting such a small number of 
cells. However, the lack of cytokine production by cells coming from such an 
inflammatory environment strongly suggests that these skin-derived FOXP3+ cells are 
indeed Tregs. 
 
These studies raise interesting points about the use of FOXP3 as a marker in vitro and 
in vivo. In in vitro conditions it is clear that FOXP3 is an activation marker in 
conventional T cells; however, in the highly-inflammatory conditions of a secondary 
immune response, FOXP3 only seemed to be expressed by cells which appeared to be 
regulatory T cells. It is plausible that FOXP3 is expressed after stimulation only in the 
absence of the complex cytokine environment found in vivo, suggesting that its use as 
a definitive human Treg marker for in vivo and ex vivo work is valid. Additionally, the 
cells were stimulated using beads coated in anti-CD3 and anti-CD28, which is an 
extremely strong stimulus – far stronger than would be encountered in vivo. 
 
Another question raised by the observations made in this chapter is the source of the 
FOXP3+ cells at the site of inflammation. The cells are certainly undergoing 
proliferation throughout the course of the immune response, as seen by their high 
expression of Ki67 in both the blisters and the immunofluorescently-stained biopsy 
sections, but the expansion of FOXP3+ cells could also result from conversion of 
conventional CD4 T cells. If conversion can occur as a result of anergy, as suggested 
in Chapter 3, then the dense T cell environment of a secondary delayed type 
hypersensitivity (DTH) response could be conducive to this. Many T cells clustered Chapter 5. Human FOXP3+ Tregs in the immune response in vivo 
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together provide the perfect conditions for T:T presentation and consequent anergy 
induction. This would also generate antigen-specific Tregs, which could specifically 
protect against pathology caused by any further immune responses against this 
antigen. Further work is required to definitively ascertain the mechanism of the Treg 
expansion. New markers, such as the Treg-specific demethylated region (TSDR) [218] 
and the transcription factor, Helios [344], may be able to aid in establishing whether 
these cells result from expansion of pre-existing Tregs or conversion of conventional T 
cells at the site of inflammation. Chapter 6. Human FOXP3+ Tregs and atopic dermatitis 
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Chapter 6. Human FOXP3+ Tregs and atopic 
dermatitis 
 
6.1 Introduction 
Atopic dermatitis, also known as atopic eczema, is a hypersensitivity condition that is 
growing in prevalence in the developed world [317, 318] and causes inflammation of 
the skin with associated itching and lichenification [321]. It is commonly seen in 
children, and frequently resolves itself as they mature [316, 318]. It is known to be a 
multifactorial disease [321, 323, 324], but Tregs may have a role to play in its 
pathogenesis, since eczema-like symptoms are frequently seen in the human 
autoimmune condition IPEX, in which FOXP3 is mutated and non-functional [184, 185, 
327], as well as the murine equivalent of the disease, known as scurfy [184, 185]. 
Other studies have also implicated Tregs in atopic dermatitis [328, 332]. This study 
aimed to delineate the possible role of Tregs in atopic dermatitis (AD) by investigating 
differences in the phenotypic and functional properties of AD Tregs, compared to those 
from healthy controls. We investigated total Tregs and also the naïve and memory Treg 
subsets. 
 
The severity of the condition experienced by AD donors was measured using the EASI 
score [345, 346]. This assessment is performed by a trained dermatologist and 
allocates each component of the condition (for example, redness, lichenification and 
papulation), in each section of the body, a number – depending on the severity, from 1-
3. The EASI method also takes into account the spread of AD over the body by 
incorporating an ‘affected area score’. EASI scores in the patients studied ranged from 
the relatively mild (lowest score 0.8) to very severe (highest score 57.0). 
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6.2 Proportions of Tregs in atopic dermatitis 
In order to establish whether or not there is a deficit in the proportion of total Tregs, or 
the CD45RA+ and CD45RO+ subsets within the FOXP3 pool, peripheral blood was 
harvested from AD patients at a range of severities (EASI 1.9-57), and age-matched 
healthy controls. PBMCs were stained for expression of CD4, FOXP3, CD45RA and 
CD45RO. Although there was no difference between AD patients and healthy controls 
in the total proportion of peripheral blood CD4+ T cells expressing CD25 to a high level 
(Figure 6.1A; p=0.675, Mann-Whitney U Test), within the Treg pool, AD patients had a 
significantly decreased proportion of CD45RA+ Tregs compared to age-matched 
controls (p=0.04, Mann-Whitney U Test). This difference among Tregs was not 
reflected among conventional FOXP3- CD4+ T cells, where the proportion of CD45RA+ 
cells was no different to age-matched controls. There was a strong negative correlation 
between the proportion of Tregs expressing CD45RA and the severity of disease as 
measured by the EASI score (Figure 6.1B; p=0.003).   Chapter 6. Human FOXP3+ Tregs and atopic dermatitis 
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Figure 6.1. Composition of the CD4+, Treg (CD25
hi) and responder pools in healthy 
volunteers and patients with atopic dermatitis. 
A. Proportion of CD25
hi cells in the CD4+ T cell subset from the peripheral blood of healthy controls and 
age-matched AD patients (n=33 healthy, 17 AD). B. Left: proportion of CD25
hi CD4+ T cells expressing 
CD45RA in healthy controls and AD patients (n=33 healthy, 17 AD). Right: graph showing correlation 
between CD45RA expression in CD25
hi and EASI score in patients with atopic dermatitis (n=12). C. 
Proportion of CD4+ responders expressing CD45RA in healthy controls and AD patients (n=33 healthy, 17 
AD).   Chapter 6. Human FOXP3+ Tregs and atopic dermatitis 
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6.3 Proliferation of AD Tregs 
Having established a significant difference in the composition of the Treg pool in AD 
patients, we next sought to establish whether there was any difference in the ex vivo 
degree of proliferation, as indicated by expression of the nuclear protein, Ki67. We 
harvested PBMCs from the peripheral blood of AD patients and stained them for CD4, 
FOXP3, Ki67 and CD45RO, comparing expression of Ki67 with that among age-
matched healthy controls. Surprisingly, we found that although there was no difference 
in proliferation of the CD45RO+ Treg subset, there was a significantly lower degree of 
proliferation among CD45RA+ Tregs in AD patients than in healthy controls (healthy: 
mean 1.6%±0.2, n=9; AD: mean 0.41%±0.18, n=5; p=0.0039). There was also a 
greater degree of proliferation among CD45RO+ responder T cells in AD patients than 
in healthy controls; this may be as a result of the chronic inflammation of the tissues in 
these patients. 
 
 
 
 
   
 
 
 
 
 
Figure 6.2. Ki67 expression by T cell subsets in the peripheral blood of AD patients is 
altered from that in healthy controls. 
PBMCs from AD patients and age-matched healthy controls were stained ex vivo for the Treg markers 
CD4 and FOXP3, the differentiation marker CD45RO and the proliferation marker Ki67. Cumulative data is 
shown (healthy: n=9, AD: n=5). 
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6.4 Phenotypes of AD Tregs 
Having established a deficit in CD45RA+ Treg numbers in AD patients and also a 
discrepancy in their rate of proliferation, we sought to further characterise any potential 
functional defects in the CD45RA+ Treg population by investigating their expression of 
the markers CTLA-4 and CD39. 
 
In the case of CD39, no significant difference was found in its expression overall in 
either Treg subset (Figure 6.3B and C). However, there were two distinct groups of 
patients, expressing either normal levels of CD39 or much lower levels, among 
CD45RO+ Tregs. CD39 expression did not, however, correlate with the severity of the 
AD (Figure 6.3B, right). 
 
No difference was observed in intracellular CTLA-4 expression by CD45RA+ Tregs 
(Figure 6.4 A and B). However, a significantly increased proportion of CD45RO+ Tregs 
expressed CTLA-4 in AD patients compared to healthy controls (mean healthy 
12.1%±1.2, n=7; mean AD 24.0%±3.9, n=8; p=0.0173). CTLA-4 expression did not 
significantly correlate with CD39 expression on Tregs, either from healthy or AD 
individuals (Figure 6.4C). 
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Figure 6.3. CD39 expression on Tregs and responder T cells from AD patients in 
comparison with healthy controls.
A. Dotplots showing representative CD39 staining on Tregs (left) and responders (right) from AD patients. 
B. Left, CD39 expression by CD4+FOXP3+ Tregs in healthy controls and AD patients. (n=16 healthy, 18 
AD) Right, graph showing CD39 expression by FOXP3+ Tr
in AD patients (n=13). C. Cumulative data showing CD39 expression by CD45RO+ and CD45RA+ subsets 
in healthy controls and AD patients. (n=8 healthy, 13 AD)
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Figure 6.3. CD39 expression on Tregs and responder T cells from AD patients in 
comparison with healthy controls. 
Dotplots showing representative CD39 staining on Tregs (left) and responders (right) from AD patients. 
CD39 expression by CD4+FOXP3+ Tregs in healthy controls and AD patients. (n=16 healthy, 18 
graph showing CD39 expression by FOXP3+ Tregs compared to eczema severity (EASI score) 
Cumulative data showing CD39 expression by CD45RO+ and CD45RA+ subsets 
in healthy controls and AD patients. (n=8 healthy, 13 AD) 
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Dotplots showing representative CD39 staining on Tregs (left) and responders (right) from AD patients. 
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Figure 6.4. CTLA-4 expression on Tregs and responders from AD patients in comparison 
with healthy controls.
A. Dotplots showing representative intracellular staining of CTLA
AD patients. B. Cumulative data showing intracellular CTLA
and CD45RO+ T cell subsets. (n=7 healthy, 8 AD) 
with CD39 expression on Tregs of AD patients. (n=15) 
compared with CD39 expression on Tregs of healthy controls. (n=10)
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6.5 Functional suppressive capacity of Tregs in AD 
There does not appear to be a large phenotypic difference between the Tregs of AD 
patients and healthy controls. However, many studies have implicated defective Tregs 
in the pathogenesis of AD [328, 329, 332], and it is possible that they lack suppressive 
function. We therefore investigated functional defects in cells from AD patients– 
specifically for a lower capacity to suppress the in vitro responses of responder T cells. 
Cell numbers did not allow us to investigate suppression by CD45RA+ AD Tregs; we 
instead tested the suppressive capacity of total AD Tregs, looking at suppression of 
both proliferation and release of pro-inflammatory cytokines. 
 
6.5.1 Suppression of proliferation 
PBMCs were harvested from fresh blood from healthy controls and AD patients, 
simultaneously, and CD25
hi Tregs and CD25- responders isolated and incubated in a 
standard suppression assay set-up at a ratio of 1:1. No significant difference was 
observed in the suppression of AD responders by AD Tregs, compared to that of 
healthy responders by healthy Tregs (Figure 6.5). Although only two experiments were 
performed, this supports previous data obtained by our group [334]. 
 
 
 
 
 
 
 
 
 
 
Figure 6.5. AD and healthy Tregs are equally capable of suppressing proliferation of 
responder T cells. 
Representative graph showing results of suppression assays performed in triplicate with healthy responder 
T cells and Tregs (black bars) and AD responder T cells and Tregs (hashed bars). Graph is representative 
of two independent experiments. 
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6.5.2 Suppression of cytokine production 
Proliferation is only one measure of a T cell response to stimulation: activated CD4+ T 
cells can release a range of cytokines, many pro-inflammatory, including interferon 
gamma (IFN-γ) and interleukin-2 (IL-2). In order to investigate whether AD Tregs have 
a defect in their capacity to suppress the release of inflammatory cytokines, cytokine 
suppression assays were set up with Tregs and responders at a ratio of 1:1. Cells from 
AD patients and healthy controls were investigated at the same time and cells were 
stained for production of the cytokines IL-2, IFN-γ, IL-4 and TNF. No difference 
between AD and healthy Tregs was found in suppression of any cytokine tested, 
although we did not observe any suppression of TNF production, by either healthy 
donors or AD patients (Figure 6.6). 
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Figure 6.6. AD and healthy Tregs are equally capable of suppressing cytokine 
production. 
CD4+CD25
hi and CD4+CD25
responders were stained with CFSE, to differentiate them from the Tregs, and the subsets were incubated 
together or separately with anti
PMA and ionomycin and secretion was block
and IFN-γ production by responders alone (top) and when cocultured with CD25
patients compared to healthy controls. 
cytometry. Two independent experiments
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and CD4+CD25- T cells were isolated from AD patients and age-matched healthy co
responders were stained with CFSE, to differentiate them from the Tregs, and the subsets were incubated 
together or separately with anti-CD3, anti-CD28-coated beads for 42 hours. They were restimulated with 
PMA and ionomycin and secretion was blocked with brefeldin A. A. Representat
 production by responders alone (top) and when cocultured with CD25
patients compared to healthy controls. B. Cytokine production in each subset was measured using flow 
wo independent experiments are shown. 
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6.6 Skin homing of Tregs in atopic dermatitis 
Although total Tregs from AD patients appear to be functionally indistinguishable from 
their healthy counterparts in vitro, Tregs may nevertheless be implicated in AD in vivo,  
functioning less well in certain cytokine environments, or at low Treg:Teffector ratios, 
than healthy Tregs. There is also the possibility that they may be entirely functionally 
competent but have impaired migratory capacity, leaving them unable to reach areas of 
inflammation in the skin. In the final part of this study, we investigated the migration of 
AD Tregs, looking at their homing marker expression and their presence in the skin of 
AD patients in vivo. 
 
6.6.1 AD Tregs show a similar degree of CLA expression to Tregs 
from healthy controls 
CLA is a skin-specific homing marker [306], which binds E-selectin on the surface of 
activated endothelium [119, 120] and is known to be expressed by a large proportion of 
memory Tregs in healthy individuals ([314, 315]; Chapter 4). No difference in the 
proportion of either CD45RA+ or CD45RO+ Tregs expressing CLA was observed in AD 
patients compared to healthy controls, as shown in Figure 6.7. This suggests that the 
capacity of Tregs from AD patients to reach the inflamed site is unimpaired (healthy: 
mean 42.7%±4.7 CD45RO+ Tregs, 16.4%±4.7 CD45RA+ Tregs, n = 12; AD: mean 
49.7%±7.7 CD45RO+ Tregs, 11.7%±2.8 CD45RA+ Tregs, n = 6).   Chapter 6. Human FOXP3+ Tregs and atopic dermatitis 
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Figure 6.7. Similar CLA expression by Tregs and non-Tregs in atopic dermatitis patients 
and healthy controls. 
Peripheral blood mononuclear cells from AD patients and age-matched controls were stained for 
expression of CD4, FOXP3, CD45RA, CD45RO and CLA. CLA expression by T cell subsets was 
compared in the two groups. No significant difference in CLA expression between healthy and AD subjects 
was found in any CD4+ T cell subset. 
 
 
 
6.6.2 CD4+ FOXP3+ cells are present in the skin of AD patients 
Punch biopsies were taken from the lesional and nonlesional skin of AD patients (n=7 
lesional, 8 nonlesional) and sections were stained for CD4 and FOXP3. CD4+ cells in 
the five largest infiltrates in each section were counted and the proportion expressing 
FOXP3 compared to that in unchallenged skin sections from healthy donors. Contrary 
to previous reports [103], FOXP3+ cells were seen in AD sections (Figure 6.8B, C). 
The proportion of CD4+ cells expressing FOXP3 in both lesional and nonlesional AD 
skin was higher than that in normal, uninflamed skin (Figure 6.8D and see Chapter 5) 
and this was significant in nonlesional AD skin (mean 24.5%±2.9; unchallenged normal 
skin: mean 13.64%±1.7, see Chapter 5; p=0.0024), although not in lesional skin (mean 
proportion of CD4+ expressing FOXP3 20.2%±3.4; p=0.068). There was, however, no 
significant difference between the proportions of CD4+FOXP3+ cells in lesional 
compared to nonlesional AD skin (p=0.35). 
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Figure 6.8. FOXP3+ cells are present in skin from atopic dermatitis patients. 
Punch biopsies were taken from healthy controls and lesional and nonlesional AD skin, and sections 
stained for CD4 and FOXP3. A. Representative picture showing expression of CD4 (green) and FOXP3 
(red) in normal, unchallenged skin. B. Representative picture showing expression of CD4 and FOXP3 in 
lesional AD skin. C. Representative picture showing expression of CD4 and FOXP3 in nonlesional AD 
skin. D. Graph showing proportions of CD4+ cells expressing FOXP3 in lesional and nonlesional AD skin 
sections (n= 8 lesional, 7 nonlesional). Data from healthy subjects (Chapter 5) are shown for comparison. Chapter 6. Human FOXP3+ Tregs and atopic dermatitis 
 
135 
 
6.6.3 FOXP3+ cells are not proliferating in nonlesional AD skin but 
show Ki67 expression in lesional skin. 
In order to establish the rate of proliferative activity of Tregs in AD skin, we also 
investigated lesional and nonlesional AD skin sections for coexpression of FOXP3 and 
the nuclear proliferation marker, Ki67. We found that very low proportions of FOXP3+ 
cells in nonlesional skin were in cycle (mean 0.91%±0.7, n=7), whereas a significantly 
higher proportion of FOXP3+ cells from lesional skin were proliferating (mean 
5.00%±1.6, n=6, p=0.0339). 
In comparison, unchallenged (day 0) healthy skin shows virtually no Ki67 expression in 
any cells in perivascular infiltrates (not shown). Following subcutaneous challenge of 
healthy skin with PPD, a higher degree of Ki67 expression is seen among FOXP3+ 
cells (day 3: mean 9.7%±1.1; day 7: mean 8.1%±2.5; day 14: mean 7.9%±1.8; see 
Chapter 5). Nonlesional skin displayed a significantly lower degree of proliferation than 
that seen during a secondary immune response (nonlesional AD skin compared to 
healthy challenged skin: day 3, p<0.0001; day 7, p=0.017; day 14, p=0.003) whereas 
the degree of proliferation seen among FOXP3+ cells in lesional AD skin is not 
significantly different from healthy challenged skin (lesional AD skin compared to 
healthy challenged skin: day 3, p=0.067; day 7, p= 0.3343; day 14, p= 0.2639), 
although lower (see Figure 6.9C and Chapter 5).   Chapter 6. Human FOXP3+ Tregs and atopic dermatitis 
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Figure 6.9. FOXP3+ cells in AD patients show a low degree of Ki67 expression in both 
lesional and nonlesional skin. 
A. Representative staining of FOXP3 (red) and Ki67 (green) in nonlesional skin from an AD patient. B. 
Representative staining of FOXP3 (red) and Ki67 (green) from AD lesional skin. C. Cumulative data 
showing the proportion of FOXP3+ cells expressing Ki67 in lesional and nonlesional skin. (n=6 lesional, 7 
nonlesional). Data from healthy subjects (Chapter 5) are shown for comparison.   Chapter 6. Human FOXP3+ Tregs and atopic dermatitis 
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6.7 Discussion 
Atopic dermatitis (AD), along with other hypersensitivity conditions such as asthma, is a 
condition on the increase in the developed world. Worldwide, it affects approximately 
20% of children, though on average around 60% of childhood cases resolve by the 
time the child reaches adulthood [320]. 
 
Tregs were implicated in the pathogenesis of AD by the identification of eczema-like 
symptoms associated with the autoimmune syndrome IPEX (immune dysregulation, 
polyendocrinopathy, X-linked syndrome), in which the FOXP3 gene is mutated and the 
protein non-functional [184, 185]. A high proportion of IPEX sufferers present with 
eczema-like symptoms [327]; this implies that a deficit of Tregs can make individuals 
prone to atopic dermatitis, which suggests that Tregs have a role in preventing the 
disease. A similar condition (scurfy) exists in mice, and the symptoms also often 
include an eczema-like condition, with scaly, inflamed skin [184, 185]. Despite this 
circumstantial evidence, a deficit in Treg numbers or function in AD patients has yet to 
be proven [330-332, 334], though some studies have observed defective suppression 
by AD Tregs [328]. In this study we aimed to investigate this aspect of AD 
pathogenesis further, by studying the phenotype, migratory capacity and suppressive 
ability of AD Tregs and, particularly, the CD45RO+ and CD45RA+ subsets within the 
Treg pool of AD patients. 
 
We found that a significantly lower proportion of Tregs from AD patients than healthy 
controls expressed the naïve marker, CD45RA. There is no difference, however, in the 
proportion of naïve responder T cells, but this cannot rule out the possibility that high 
levels of inflammation prevalent in these patients may increase the transition of  
CD45RA+ Tregs to a CD45RO+ phenotype. In addition, however, there was a lower 
degree of proliferation among these CD45RA+ Tregs, which is surprising: previous 
studies have indicated that the smaller the naïve subset, the greater the degree of 
cycling taking place within it [339], so the opposite phenomenon might have been 
expected. It is possible, however, that CD45RA+ Tregs may convert to CD45RO 
expression more rapidly in AD patients than in healthy controls, reducing the number of 
proliferating cells still expressing CD45RA. 
 
We found no difference in the suppressive capacity of AD and healthy Tregs, when 
used with responders at a 1:1 ratio, either when looking at their effect on proliferation or 
on cytokine production. However, two areas of interest were unable to be investigated Chapter 6. Human FOXP3+ Tregs and atopic dermatitis 
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in this project, due to the difficulty in obtaining significant quantities of blood from AD 
patients. Firstly, using Tregs at a ratio of 1:1 is not physiological, and defects may be 
apparent at lower ratios that are missed at this level. Additionally, having identified a 
potential defect in the number and perhaps proliferation of CD45RA+ Tregs, 
suppression assays using the two Treg subsets may be highly informative. The 
suppression assays were also performed using a non-physiological stimulus, anti-CD3, 
anti-CD28 coated beads. It may be more informative to repeat the experiment using 
APCs and an antigenic stimulus, perhaps a common allergen such as dust-mite 
allergen or cat dander, although previous experiments using these stimuli have also 
found no difference between the capacity of AD and healthy Tregs to suppress 
responder proliferation [334]. Additional factors in vivo that impact on the ability of 
Tregs to suppress AD responses are also unlikely to be present in the artificial 
environment of the in vitro suppression assay: responder CD4+ T cells may be harder 
to suppress in AD conditions. Investigation of the function of Tregs from skin would 
also be useful, as these cells may differ from Tregs isolated from the blood. 
 
Phenotypically, we identified a number of differences between AD and healthy Tregs. 
CTLA-4 expression is, counterintuitively, more prevalent on the regulatory T cells from 
atopic individuals. It is possible that this could be the result of activation, since many of 
the AD patients have widespread disease; it is unlikely to be upregulated to 
compensate for any defect caused by lack of CD39, as there is no negative correlation 
between the degrees of expression of the two markers. Although there is no consistent 
and significant defect in expression of CD39 in AD patients, there does appear to be a 
subgroup with very low expression of the marker, a phenomenon not present among 
healthy individuals. This is intriguing, as CD39 has been suggested to play a tolerising 
role when expressed on Langerhans cells, dendritic cells in the skin [347]. Future 
investigation of CD39 expression in AD patients, specifically in the skin, would be 
desirable to establish whether there may in fact be a role for this molecule in the 
pathogenesis of atopic dermatitis. It was not possible to obtain detailed histories of the 
AD patients involved in this study, although no connection with age at diagnosis and 
expression of CD39 or CD45RA could be established, but a longitudinal study may be 
informative: perhaps those with higher levels of CD39 expression have flare-ups that 
resolve more rapidly. 
 
Contrary to some previous reports [329], FOXP3+ cells are present and indeed fairly 
numerous in both lesional and nonlesional AD skin. Although not a significant 
difference, there tends to be a higher proportion of CD4+ T cells expressing FOXP3 in Chapter 6. Human FOXP3+ Tregs and atopic dermatitis 
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nonlesional skin than lesional areas. There is also a significantly higher proportion of 
CD4+ cells expressing FOXP3 in nonlesional AD skin than in unchallenged normal 
skin. Nonlesional skin is not conventional, uninflamed skin – almost all of the AD 
patients recruited had widespread eczema and the biopsied nonlesional areas are 
highly likely to be regions of resolving or recently-resolved inflammation, which could 
explain the high levels of FOXP3+ cells shown. AD patients also had large perivascular 
infiltrates in all sections investigated, which are not observed in unchallenged, normal 
skin. 
 
Interestingly, although present in high numbers, the FOXP3+ cells in nonlesional skin 
were not dividing: the proportion expressing Ki67 was consistently significantly lower 
than that seen throughout a normal secondary cutaneous immune response. 
Conversely, a higher degree of Ki67 expression was observed in lesional areas, not 
significantly different from that seen during an immune response. Given the high 
proportions of FOXP3+ cells seen in nonlesional skin, their low degree of proliferation 
is a curious observation. Lesional areas are regions of active inflammation, with large 
infiltrates visible within the skin, and would be expected to show a large degree of 
proliferation by Treg as well as responder cells. Ki67 was extensively expressed in 
non-FOXP3+ cells within the AD perivascular infiltrates. 
 
Initial investigations showed a strong degree of proliferation among FOXP3- cells in the 
AD infiltrates both in lesional and nonlesional skin (Figure 6.9 and not shown). An 
extension to this investigation would be to stain for Ki67 expression by CD4 cells at 
lesional and nonlesional sites, to determine whether CD4+ T cells in general in AD 
infiltrates are dividing, or whether the low rate of proliferation is restricted to Tregs. 
Future investigations into the proliferative capacity of AD Tregs may be informative; if 
there is a defect in their ability to divide as much as infiltrating responders, this would 
be likely to hinder their capacity to control inflammation. 
 
In summary, no functional deficit of AD Tregs could be determined using an APC-free 
stimulus in vitro. However, the unexpectedly low proliferative rate of CD45RA+ Tregs in 
the blood and FOXP3+ cells in the skin suggests that perhaps there may be some 
defect in the generation or – given the low cycling rate – the maintenance of thymically-
derived Tregs in atopic individuals. If true, this could help to explain why AD is relatively 
common in children and less so in adults: initially young children have largely naïve 
cells and are heavily reliant on the naïve subset, but as they grow older and are Chapter 6. Human FOXP3+ Tregs and atopic dermatitis 
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exposed to more antigens, Tregs are generated via peripheral conversion, allowing 
them to ‘grow out’ of the disease.Chapter 7. Final Discussion 
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Chapter 7. Final Discussion and Future 
Directions 
 
The work presented in this thesis investigated the migration, function and age-related 
changes of the Treg compartment, particularly in relation to the CD45RO+ and 
CD45RA+ subsets within it. We investigated the phenotypic characteristics of these 
cells as well as their in vivo migratory behaviour and kinetics during a cutaneous 
immune response. We then extended our investigations to explore the potential 
contribution of these cells to the pathogenesis of the hypersensitivity condition, atopic 
dermatitis. 
 
Early investigations of a suppressive subset of T cells resulted in failure to identify a 
clear suppressive subpopulation and led to a decline in suppressor cell research [180]. 
However, in 1995, a suppressive CD25+ subset of CD4+ T cells was identified in mice 
[181] and the cells termed regulatory T cells. These cells have been extensively 
investigated since then [182, 183], but it is only recently that the small CD45RA+ 
subset of Tregs has been investigated specifically in adults [220, 221, 225]. Previous 
studies have looked at the Treg compartment as a whole [182, 183] or focused on the 
larger subset of CD45RO+ Tregs [228]. Although it is known that the Treg subset as a 
whole remains stable [348, 349] or even increases [228, 350] with age in humans, the 
CD45RA+ subset of Tregs undergoes a sharp decline [221, 351, 352], falling from 
around 80% of Tregs in cord blood [353] to around 10% by age 20, and thence to 
around 1% of the Treg pool by the age of 80, as shown in this study. This study aimed 
in part to investigate similarities and differences between CD45RA+ and CD45RO+ 
Tregs, to gain a better understanding of the source of memory regulatory T cells and 
also to establish likely changes in immune regulation with age. 
 
Our initial investigations centred on the composition of the Treg pool throughout life, 
investigating not only the basic memory and naïve markers CD45RO and CD45RA, but 
also the recently-postulated recent thymic emigrant (RTE) marker CD31 [69]. We found 
a sharp decline in the numbers of both CD45RA+ and RTE Tregs during the course of 
adult life, as has been previously reported [220, 221, 352]. As the numbers of 
CD45RA+ Tregs declined, the degree of proliferation within this subset increased so 
that older people had significantly more proliferation among their naïve Tregs than Chapter 7. Final Discussion 
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young adults did; this is likely to be a direct consequence of the smaller CD45RA+ pool 
in the elderly, as it has been previously reported that smaller pools of naïve cells 
proliferate to a greater extent [339]. Notably, the degree of proliferation among 
CD45RO+ Tregs was lower in the old, perhaps because the pool of memory Tregs is 
by then very highly-differentiated and approaching senescence [353]. This implies that 
the greater degree of proliferation among CD45RA+ Tregs in the old may have some 
compensatory effect, to help maintain Treg numbers despite a lower degree of memory 
cell proliferation. 
 
Overall, the degree of proliferation shown by CD45RO+ was significantly higher than 
that among CD45RA+ Tregs and remained consistently so within individuals over time. 
Turnover within the Treg pool as a whole has been shown previously to be rapid in vivo 
[228, 354] but the degree of proliferation among CD45RA+ Tregs was not known at the 
outset of this investigation. Although much lower than memory Tregs, proliferation 
among CD45RA+ Tregs is nevertheless significantly higher than that among other 
naïve CD4+ T cells, suggesting a propensity for frequent cell division among cells that 
express FOXP3. However, although a high proportion of Treg cells are proliferating at 
any given time, it is currently impossible to rule out the possibility that there may be a 
small proportion of long-lived memory Tregs which turn over at a slow rate and are not 
identified with Ki67 staining. CD45RA+ Tregs did show Ki67 expression to a much 
lower degree than CD45RO+ Tregs, probably because on stimulation they rapidly 
convert to express CD45RO. However, within the naive CD45RA+ Treg subset we did 
note a higher degree of proliferation among CD31+, ‘recent thymic emigrant’ cells, than 
among CD31- cells. This could be due to residual Ki67 expression from thymic turnover 
[341]. Additionally, recent studies have shown that some cytokines can allow 
CD45RA+CD31+ cells to divide without losing expression of CD31 [355], which may 
partly explain this phenomenon. 
 
CD45RO+ and CD45RA+ Tregs are phenotypically distinct, expressing different levels 
of the Treg markers CD39 and CTLA-4.This may reflect their different activation states, 
since both CTLA-4 and CD39 are known to be activation markers as well as Treg-
expressed proteins [204, 217]. Although CD45RA+ Tregs express much lower levels of 
these markers, they appear equally competent at suppressing responder T cell 
proliferation and cytokine production at a 1:1 ratio. Both molecules have been 
implicated in Treg function [59, 215, 216, 257] but investigations in this study 
demonstrated that Tregs not expressing CD39 are able to suppress responses at a 
timepoint when CD39 has not been significantly upregulated, suggesting that they are Chapter 7. Final Discussion 
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able to function via a CD39-independent mechanism. This is likely to be true for the 
largely CD39-, CTLA-4- population of CD45RA+ Tregs as well. Preliminary 
investigations suggest that CD45RA+ Tregs are less able than CD45RO+ cells to 
suppress responses at lower ratios than 1:1 (data not shown), perhaps as a result of 
different modes of action able to affect differing numbers of target cells. Further 
investigation of this area is required to establish to what extent CD45RA+ and 
CD45RO+ may function differently, as the changing ratios of these cells through adult 
life could therefore have considerable implications on the maintenance of tolerance into 
old age. Future studies incorporating siRNA silencing of the CD39 gene in CD45RO+ 
Tregs may provide further insight into the involvement of this molecule in their function. 
Since CTLA-4 is not expressed on a large proportion of resting CD45RA+ Tregs, 
investigations into the kinetics of upregulation of this molecule may also be informative. 
 
An area of some debate at the present time is the proportion of Tregs derived directly 
from FOXP3+ cells generated in the thymus and the proportion derived from responder 
CD4+ T cells induced to express FOXP3 in the periphery [356, 357]. This study 
demonstrates that the potential of CD45RA+ Tregs to become CD45RO+ cells is 
entirely normal, but cannot provide an answer to the question of relative contributions 
of the two sources. However, work presented in this thesis proposes a novel 
mechanism of conversion of responders to acquire suppressive capacity, via anergy 
induction. Anergised cells showed unresponsiveness to stimulation in vitro and were 
able to suppress the proliferation of control, non-anergised CD4+ T cells. This 
scenario, in which the induction of anergy results in suppressive cells, lends itself to in 
vivo uses: activated T cells are known to be able to present antigen to each other on 
upregulated MHC class II molecules and this T:T presentation is also known to lead to 
anergy [170, 171]. Therefore, in a situation where there is a great deal of inflammation 
and a large influx of T cells in a confined region, it is highly plausible that these cells 
could present self- or foreign antigen to one another and thereby induce antigen-
specific Tregs. This would be a highly effective safety mechanism preventing immune 
responses from spreading beyond control. This also has the potential to be exploited in 
the clinic in the case of allergy or autoimmune diseases: antigen-specific T cells that 
are the cause or a contributing factor to the disease in question could be removed, 
anergised and used to bring it specifically to an end without, theoretically, causing 
generalised immune suppression, as these cells would already be primed to travel to 
the site of immunopathology. 
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The distinction between CD45RA+ and CD45RO+ Tregs has been previously 
investigated to some extent, but their relative migratory behaviour in vivo has not yet 
been studied. However, differing migratory behaviour could indicate different 
requirements for survival or discrete roles within the immune system. We showed 
distinct migratory patterns for the two subsets, with CD45RA+ Tregs appearing 
enriched in the bone marrow and CD45RO expression almost universal among Tregs 
in the skin. In addition, although CD45RO+ Tregs and responders readily crossed 
activated dermal endothelium in vitro, naïve cells showed no such ability. 
 
CD45RO+ cells can be assumed to have been previously primed, as they have 
downregulated expression of CD45RA and upregulated CD45RO instead, a post-
activation event [65]. A very large proportion of CD45RO+ regulatory T cells is known 
to express CLA [314, 315]. CD45RA+ Tregs do not express skin-homing markers like 
CLA and CCR4 to a great extent and in contrast express high levels of the bone 
marrow-homing chemokine receptor CXCR4, a combination not unexpected in naïve 
cells [358], and a similar pattern of homing marker expression was seen in CD45RA+ 
CD4+ responders, although the latter expressed somewhat less of both types of 
marker. However, naïve Tregs were significantly enriched in the bone marrow, whereas 
no enrichment was seen among naïve responders. The purpose of such enrichment is 
not yet known, but it seems reasonable to propose that the bone marrow may play a 
role in the maturation and development of these undifferentiated cells. It has been 
shown to have the ability to act as a secondary, as well as a primary, lymphoid organ, 
providing a site in which antigen presentation can take place [359]; perhaps it plays a 
role in the initial activation of naïve Tregs. Alternatively, its specific microenvironment 
[342] may provide an environment conducive to naïve Treg maintenance until they 
need to be activated and migrate to sites of inflammation. IL-7 has been shown to 
contribute to the maintenance of naïve conventional T cells [355, 360] but regulatory T 
cells express low levels of the IL-7 receptor, CD127, and naïve Tregs are no exception. 
Therefore it is possible that an alternative cytokine may be required to sustain the 
CD45RA+ Treg pool and that this is prevalent in the bone marrow. Additionally, the 
cytokine milieu of the bone marrow may allow CD45RA+ Tregs to proliferate without 
losing expression of CD45RA. Cumulatively, these data indicate that CD45RO+ and 
CD45RA+ Tregs occupy discrete niches in the immune system. 
 
Identifying Tregs in situations involving a high degree of inflammation is currently a 
difficult task, due to the phenomenon whereby activated human T cells transiently 
express FOXP3 [193-196]. Although true Tregs can be identified as distinct from Chapter 7. Final Discussion 
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activated T cells on the basis of demethylation of a promoter region of the FOXP3 gene 
[218], this is not practical to use as an identifying marker in all situations. This study 
has confirmed the transient nature of FOXP3 expression in activated T cells, which 
seems strongly linked to cell division as Ki67 expression by FOXP3+ activated cells 
was almost universal. However, this thesis demonstrates that FOXP3 expression in the 
context of a secondary cutaneous response was limited to cells that did not produce 
cytokines, when restimulated, in any notable quantities, unlike other CD4-expressing 
cells isolated from the site, which did not express FOXP3 but produced IFN-γ and IL-2 
in significant quantities on restimulation. FOXP3+ cells isolated from the site of in vivo 
inflammation therefore appeared to be regulatory T cells, although due to their 
exceptionally small numbers, their suppressive capacity could not be tested directly. 
This study therefore suggests that FOXP3 expression in vivo in humans is a much 
more reliable marker of regulatory activity, even at the site of ongoing inflammation, 
than it is under inflammatory conditions in vitro. This has important ramifications for the 
study of regulatory T cells in humans. 
 
Atopic dermatitis is a hypersensitivity condition that has affected increasing numbers in 
the developed world in recent decades, particularly children [318, 319]. Atopic 
conditions have been suggested to be linked to one another – for example, eczema 
and asthma [322]. If this is so, it means that the study of atopic dermatitis is important 
not just to gain a better understanding of the causes underlying this disease, but also 
other conditions such as asthma. Unlike other atopic conditions, however, AD affects a 
particularly accessible organ: the skin. Work in this thesis indicates that there may 
indeed be a defect in aspects of Treg function in patients with AD, but in aspects not 
directly linked to their suppressive function. We found that although Tregs were highly 
prevalent in the skin of AD patients, particularly in lesional skin but even in skin that 
was not currently actively inflamed, they were not dividing at a particularly high rate. 
Additionally, the CD45RA+ regulatory T cell pool was not only much smaller in AD 
patients than healthy controls but also contained a smaller proportion of dividing cells. 
Given previous work suggesting that smaller pools of naïve cells show a higher degree 
of proliferation [339] this is an intriguing finding and, added to the low rate of Treg 
proliferation in AD lesional skin, a situation that could be equated to acute inflammation 
and would therefore be expected to entail high levels of proliferation (as shown in 
Chapter 5), this suggests a potential proliferative defect among AD Tregs. It is of note 
that, as shown in the photographs in Chapter 6, Ki67 expression among other cells in 
inflammatory AD infiltrates was high. Nevertheless, no defect in suppression was found 
in the suppression assays conducted in this study. There may be a number of reasons Chapter 7. Final Discussion 
 
146 
 
for this. First, the suppression assays were performed in vitro using an APC-free 
system, so the influence of antigen presenting cells, or of Tregs on these cells, was not 
investigated. Additionally, an in vitro assay cannot replicate the inflammatory conditions 
present in the skin of an AD patient during a flare-up of atopic dermatitis. There may be 
cytokines or other factors present in inflamed AD skin which interfere with Treg 
suppression. Finally, the AD Tregs used in the study were isolated from the peripheral 
blood. These cells may behave differently from the Tregs present at the site of 
inflammation in AD skin. 
 
Additionally, a number of patients displayed a very limited degree of CD39 expression 
on their Tregs. The scope of this investigation did not extend to CD39 expression on 
other cell types, but it raises the possibility that there may be a generalised low level of 
CD39 expression in some people. Although CD39 does not seem to be necessary for 
Treg-mediated suppression, as shown in work for this thesis, it has been suggested to 
play a role in cutaneous immune regulation by Langerhans cells [347]. If expression of 
CD39 by these cells is also shown to be lower, this may be a contributory factor to the 
cutaneous inflammation seen in AD patients. Also for the future, Th17 cells have been 
implicated in AD [76] and there is known to be a finely-balanced relationship between 
Treg and Th17 development [361]. Future investigations could focus on the prevalence 
of Th17 cells, particularly in the skin at sites of active lesions in AD patients. In addition, 
investigation of the ability of AD and healthy Tregs to suppress the production of IL-17 
by responder T cells may yield interesting results. 
 
This thesis investigated the changes occurring within the Treg pool throughout life and 
atopic disease. During ageing, the composition of the Treg pool undergoes a 
fundamental change in that memory CD45RO+ cells become increasingly prevalent. 
These appear to be largely different from CD45RA+ Tregs, migrating preferentially to 
different tissues and proliferating to a greater extent, despite having shorter telomeres 
than their naïve counterparts. We suggest that the two subsets of Tregs, while both 
important throughout life, may be dominant at different stages. CD45RA+ Tregs are 
essential during youth to mediate self-specific regulation and to prevent autoimmunity. 
During ageing, CD45RO+ memory Tregs, particularly those derived from conventional 
CD4+ T cells, become increasingly important, protecting against chronic inflammation. 
In atopic dermatitis, CD45RO+ cells form an abnormally high proportion of the 
peripheral blood Treg pool, yet in many patients, do not express CD39. There also 
appears to be a defect in proliferation of AD Tregs, despite their strong presence in AD Chapter 7. Final Discussion 
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lesional and nonlesional skin. All these factors may contribute to exacerbate the 
disease. References 
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